<SEC-DOCUMENT>0001104659-23-098724.txt : 20230907
<SEC-HEADER>0001104659-23-098724.hdr.sgml : 20230907
<ACCEPTANCE-DATETIME>20230906203100
ACCESSION NUMBER:		0001104659-23-098724
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20230906
FILED AS OF DATE:		20230907
DATE AS OF CHANGE:		20230906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Profound Medical Corp.
		CENTRAL INDEX KEY:			0001628808
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39032
		FILM NUMBER:		231240756

	BUSINESS ADDRESS:	
		STREET 1:		2400 SKYMARK AVENUE, UNIT 6
		CITY:			MISSISSAUGA
		STATE:			A6
		ZIP:			L4W 5K5
		BUSINESS PHONE:		647-476-1350

	MAIL ADDRESS:	
		STREET 1:		2400 SKYMARK AVENUE, UNIT 6
		CITY:			MISSISSAUGA
		STATE:			A6
		ZIP:			L4W 5K5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Profound Medical Inc.
		DATE OF NAME CHANGE:	20141222
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2325456d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT><B><BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16<BR>
UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of September&nbsp;2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number:&nbsp;<B>001-39032</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>PROFOUND
MEDICAL CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>(Translation of the registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2400
Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5</B></FONT><BR>
(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;Form&nbsp;40-F&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibits 99.2, 99.3 and 99.4 of this Form&nbsp;6-K
of Profound Medical Corp. (the &ldquo;Company&rdquo;) are hereby incorporated by reference into the Registration Statement on Form&nbsp;F-10
(File No.&nbsp;333-263248) of the Company, as amended or supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following documents, each of which is attached as an exhibit hereto,
and is incorporated by reference herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit</U></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Title</U></B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 6%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 93%">&nbsp;</TD></TR>
  <TR>
    <TD><A HREF="tm2325456d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2325456d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated September&nbsp;6, 2023</FONT></A></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><A HREF="tm2325456d1_ex99-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2325456d1_ex99-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Distribution Agreement</FONT></A></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><A HREF="tm2325456d1_ex99-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2325456d1_ex99-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Mintz LLP dated September&nbsp;6, 2023</FONT></A></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><A HREF="tm2325456d1_ex99-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2325456d1_ex99-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Osler, Hoskin&nbsp;&amp; Harcourt LLP dated September&nbsp;6, 2023</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>PROFOUND MEDICAL CORP.</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(Registrant)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif">Date: September&nbsp;6, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center">/s/ Rashed Dewan</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Rashed Dewan</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2325456d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;<B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="tm2325456d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Profound Medical
Announces At-the-Market Offering of up to US$30,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TORONTO, ON (September 6, 2023)</B> - Profound
Medical Corp. (TSX: PRN; NASDAQ: PROF) (&ldquo;<B>Profound</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;) announces that it has established
an at-the-market equity program (the &ldquo;<B>ATM Program</B>&rdquo;) that allows the Company, through certain securities dealers acting
as agents (together, the &ldquo;<B>Agents</B>&ldquo;), to issue and sell from time to time up to US$30,000,000 of common shares in the
capital of the Company (the &ldquo;<B>Common Shares</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any Common Shares sold under the ATM Program will
be made through &ldquo;at-the-market distributions&rdquo; as defined in the Canadian Securities Administrators&rsquo; National Instrument
44-102 - <I>Shelf Distributions</I>, including sales made through the Toronto Stock Exchange (the &ldquo;<B>TSX</B>&rdquo;) or the Nasdaq
Stock Market LLC (the &ldquo;<B>Nasdaq</B>&rdquo;) or on any other trading market for the Common Shares. The TSX has conditionally approved
the listing of the Common Shares that may be issued under the ATM Program and listing will be subject to the Company fulfilling all of
the listing requirements of the TSX. Distributions of the Common Shares under the ATM Program will be made pursuant to the terms of an
equity distribution agreement dated September 6, 2023 (the &ldquo;<B>Distribution Agreement</B>&rdquo;) between the Company and the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales of Common Shares, if any, will be made
at the market prices prevailing at the time of each sale and, as a result, prices may vary as between purchasers and during the period
of the ATM Program. The volume and timing of distributions under the ATM Program will be determined at the Company&rsquo;s discretion.
The ATM Program will be effective until the earlier of the issuance and sale of all of the Common Shares issuable pursuant to the ATM
Program and April 23, 2024, unless terminated prior to such date in accordance with the terms of the Distribution Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering of the Common Shares under the ATM
Program will be made pursuant to a prospectus supplement dated September 6, 2023 (the &ldquo;<B>Prospectus Supplement</B>&rdquo;) to the
Company&rsquo;s short form base shelf prospectus dated March 23, 2022 (the &ldquo;<B>Base Shelf Prospectus</B>&rdquo;), which were each
filed with the applicable securities regulatory authorities in each of the provinces and territories of Canada, and in the United States
pursuant to a prospectus supplement dated September 6, 2023 (the &ldquo;<B>U.S. Prospectus Supplement</B>&rdquo;) to the Company&rsquo;s
U.S. base shelf prospectus (the &rdquo;<B>U.S. Base Shelf Prospectus</B>&ldquo;) included in its registration statement on Form F-10,
as amended (File No. 333-263248) (the &ldquo;<B>Registration Statement</B>&rdquo;), filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The timing and extent of the use of the ATM Program
will be at the discretion of the Company. Accordingly, total gross proceeds from equity offerings under the ATM Program could be significantly
less than US$30,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the net proceeds of
the Offering, if any: (i) to fund the continued commercialization of the TULSA-PRO<SUP>&reg;</SUP> system in the United States, (ii) to
fund the continued development and commercialization of the TULSA-PRO<SUP>&reg;</SUP> system and the Sonalleve<SUP>&reg;</SUP> system
globally, and (iii) for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copies of the Distribution Agreement, the Prospectus
Supplement and the Base Shelf Prospectus are available on SEDAR+ at <U>www.sedarplus.ca</U> and the Distribution Agreement, the U.S.
Prospectus Supplement, the U.S. Base Prospectus and the Registration Statement are available on EDGAR at <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copies of the Distribution Agreement, the Prospectus
Supplement, the Base Shelf Prospectus, the U.S. Prospectus Supplement, the U.S. Base Shelf Prospectus and the Registration Statement may
also be obtained directly from the Company at 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, L4W 5K5, Telephone: (647) 476-1350.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No securities regulatory authority has either
approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Profound Medical Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is a commercial-stage medical device
company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is commercializing TULSA-PRO<SUP>&reg;</SUP>,
a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO<SUP>&reg;</SUP>
is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting
the urethra and rectum to help preserve the patient&rsquo;s natural functional abilities. TULSA-PRO<SUP>&reg;</SUP> has the potential
to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer,
retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia
(BPH). TULSA-PRO<SUP>&reg;</SUP> is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is also commercializing Sonalleve<SUP>&reg;</SUP>,
an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Sonalleve<SUP>&reg;</SUP> has also been approved by the China National Medical Products Administration for the non-invasive treatment
of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in
the early stages of exploring additional potential treatment markets for Sonalleve<SUP>&reg;</SUP> where the technology has been shown
to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking statements
regarding Profound and its business which may include, but are not limited to, statements with respect to the ATM Program, including the
use of proceeds thereof, the expected ATM Program jurisdictions, and the expectations regarding the efficacy of Profound&rsquo;s technology
in the treatment of prostate cancer, uterine fibroids and palliative pain treatment. Often, but not always, forward-looking statements
can be identified by the use of words such as &quot;plans&quot;, &quot;is expected&quot;, &quot;expects&quot;, &quot;scheduled&quot;,
 &quot;intends&quot;, &quot;contemplates&quot;, &quot;anticipates&quot;, &quot;believes&quot;, &quot;proposes&quot; or variations (including
negative variations) of such words and phrases, or state that certain actions, events or results &quot;may&quot;, &quot;could&quot;, &quot;would&quot;,
 &quot;might&quot; or &quot;will&quot; be taken, occur or be achieved. Such statements are based on the current expectations of the management
of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all
and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding
the ATM Program (including that the Company may be unsuccessful in selling Common Shares under the ATM Program or that the Company&rsquo;s
use of proceeds of the ATM Program may differ from those indicated), the pharmaceutical industry, economic factors, the equity markets
generally and risks associated with growth and competition, and the other risks described in the Prospectus Supplement, the Base Shelf
Prospectus, the U.S. Prospectus Supplement, the U.S. Base Shelf Prospectus and the Registration Statement, and the documents incorporated
by reference therein. Although Profound has attempted to identify important factors that could cause actual actions, events or results
to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results
to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. All forward-looking information
in this news release is as of the date of this news release. Except as required by applicable securities laws, forward-looking statements
speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events, or otherwise, other than as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephen Kilmer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">skilmer@profoundmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: 647.872.4849</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm2325456d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Up to US$30,000,000 of Common Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Equity Distribution Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">September&nbsp;6, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stifel Nicolaus Canada Inc.<BR>
161 Bay Street, Suite&nbsp;3800<BR>
Toronto, ON M5J 2S1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stifel, Nicolaus&nbsp;&amp; Company,&nbsp;Incorporated<BR>
One South Street<BR>
15th Floor<BR>
Baltimore, Maryland 21202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Profound Medical Corp.,
a corporation organized under the laws of the Province of Ontario, Canada (the &ldquo;<U>Company</U>&rdquo;), confirms its agreement
(this &ldquo;<U>Agreement</U>&rdquo;) with Stifel Nicolaus Canada Inc. (&ldquo;<U>Stifel</U>&rdquo;) and Stifel, Nicolaus&nbsp;&amp;
Company,&nbsp;Incorporated (&ldquo;<U>Stifel U.S.</U>&rdquo; and collectively with Stifel, the &ldquo;<U>Agents</U>&rdquo;) with
respect to the issuance and sale from time to time by the Company of common shares in the capital of the Company (&ldquo;<U>Common
Shares</U>&rdquo;, and any Common Shares sold pursuant to the terms of this Agreement are referred to herein as
 &ldquo;<U>Shares</U>&rdquo;), having an aggregate offering price of up to US$30,000,000 (or the equivalent in Canadian dollars
determined using the daily exchange rate posted by the Bank of Canada on the date the Shares are sold) (the &ldquo;<U>Maximum
Amount</U>&rdquo;) through or to the Agents, as sales agents, on the terms and subject to the conditions set forth in this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has prepared
and filed with the securities regulatory authorities (the &ldquo;<U>Canadian Qualifying Authorities</U>&rdquo;) in each of the provinces
and territories of Canada (the &ldquo;<U>Canadian Qualifying Jurisdictions</U>&rdquo;), a preliminary short form base shelf prospectus
dated March&nbsp;3, 2022 (the &ldquo;<U>Canadian Preliminary Base Prospectus</U>&rdquo;) and has prepared and filed with the Canadian
Qualifying Authorities in the Canadian Qualifying Jurisdictions the Canadian Base Prospectus (as defined herein) in respect of an aggregate
of up to US$100,000,000 (or the equivalent thereof in Canadian dollars or any other currencies) of common shares, warrants, subscription
receipts, debt securities or units comprised of a combination thereof (collectively, the &ldquo;<U>Shelf Securities</U>&rdquo;) in each
case in accordance with Canadian Securities Laws (as defined herein). The Ontario Securities Commission (the &ldquo;<U>Reviewing Authority</U>&rdquo;)
is the principal regulator of the Company under the passport system procedures provided for under Multilateral Instrument 11-102 - <I>Passport
System</I> and National Policy 11-202 - <I>Process for Prospectus Reviews in Multiple Jurisdictions</I> in respect of the Shelf Securities
and the offering of the Shares. The Reviewing Authority has issued a receipt evidencing that a receipt has been issued on behalf of itself
and the other Canadian Qualifying Authorities for the Canadian Preliminary Base Prospectus and the Reviewing Authority has issued a receipt
evidencing that a receipt has been issued on behalf of itself and the other Canadian Qualifying Authorities for the Canadian Base Prospectus
(the &ldquo;<U>Receipt</U>&rdquo;). The term &ldquo;<U>Canadian Base Prospectus</U>&rdquo; means the final short form base shelf prospectus
dated March&nbsp;23, 2022 relating to the Shelf Securities, at the time the Reviewing Authority issued the Receipt with respect thereto
in accordance with Canadian Securities Laws (as defined herein and includes all documents incorporated therein by reference and the documents
otherwise deemed to be a part thereof or included therein pursuant to Canadian Securities Laws, including but not limited to, all Designated
News Releases (as defined herein). As used herein, &ldquo;<U>Canadian Securities Laws</U>&rdquo; means the applicable securities laws
of each of the Canadian Qualifying Jurisdictions as the context may require, and the respective rules&nbsp;and regulations made under
such laws, together with applicable published national, multilateral and local policy statements, instruments, notices, rulings and blanket
orders of the Canadian Qualifying Authorities in each of the Canadian Qualifying Jurisdictions as modified by the Translation Decision
(as defined herein) ), including National Instrument 44-101 - <I>Short Form&nbsp;Prospectus Distributions</I> (&ldquo;<U>NI 44-101</U>&rdquo;)
and National Instrument 44-102 - <I>Shelf Distributions</I> (&ldquo;<U>NI 44-102</U>&rdquo;). As used herein, a &ldquo;<U>Designated
News Release</U>&rdquo; means a news release disseminated by the Company in respect of previously undisclosed information that, in the
Company&rsquo;s determination, constitutes a &ldquo;material fact&rdquo; (as such term is defined in Canadian Securities Laws) and identified
by the Company as a &ldquo;designated news release&rdquo; in writing on the face page&nbsp;of the version of such news release that is
filed by the Company on the System for Electronic Document Analysis and Retrieval Plus (&ldquo;<U>SEDAR+</U>&rdquo;) in Canada. As used
herein, &ldquo;<U>Canadian Prospectus Supplement</U>&rdquo; means the most recent prospectus supplement to the Canadian Base Prospectus
relating to the Shares filed by the Company with the Canadian Qualifying Authorities in accordance with Canadian Securities Laws. As
used herein, &ldquo;<U>Canadian Prospectus</U>&rdquo; means the Canadian Prospectus Supplement (and any additional Canadian prospectus
supplement prepared in accordance with the provisions of this Agreement and filed with the Canadian Qualifying Authorities in accordance
with Canadian Securities Laws) together with the Canadian Base Prospectus. The Canadian Prospectus Supplement shall provide that any
and all Designated News Releases shall be deemed to be incorporated by reference in the Canadian Prospectus. All Designated News Releases
shall also be filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) on Form&nbsp;6-K and the Canadian
Prospectus Supplement shall provide that such Form&nbsp;6-K shall be deemed to be incorporated by reference as an exhibit to the Registration
Statement (as defined herein). The &ldquo;<U>Translation Decision</U>&rdquo; means the decision of the Autorit&eacute; des march&eacute;s
financiers dated March&nbsp;2, 2022, obtained by the Company granting exemptive relief from the requirement that the Canadian Prospectus
and the documents incorporated by reference in the Canadian Prospectus be publicly filed in both the French and English languages. For
the purposes of the Canadian Prospectus, the Company is not required to publicly file French versions of the Canadian Prospectus and
the documents incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has also prepared
and filed with the Commission, pursuant to the Canada/U.S. Multi-Jurisdictional Disclosure System adopted by the Commission, a registration
statement on Form&nbsp;F-10 (File No.&nbsp;333-263248) covering the registration of the Shelf Securities under the Securities Act of
1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), and the rules&nbsp;and regulations of the Commission thereunder (the &ldquo;<U>Rules&nbsp;and
Regulations</U>&rdquo;), and such amendments to such registration statement as may have been permitted or required to the date of this
Agreement. Such registration statement, including the Canadian Base Prospectus (with such deletions therefrom and additions thereto as
are permitted or required by Form&nbsp;F-10 and the Rules&nbsp;and Regulations and including exhibits to such registration statement),
has become effective in such form pursuant to Rule&nbsp;467(b)&nbsp;under the Securities Act. Such registration statement on Form&nbsp;F-10,
at any given time, including amendments and supplements thereto to such time, the exhibits and any schedules thereto at such time and
the documents incorporated by reference therein at such time, is herein called the &ldquo;<U>Registration Statement</U>&rdquo;. The Canadian
Base Prospectus, with such deletions therefrom and additions thereto as are permitted or required by Form&nbsp;F-10 and the Rules&nbsp;and
Regulations in the form in which it appeared in the Registration Statement on the date it became effective under the Securities Act is
herein called the &ldquo;<U>U.S. Base Prospectus</U>&rdquo;. &ldquo;<U>U.S. Prospectus Supplement</U>&rdquo; means the most recent Canadian
Prospectus Supplement, with such deletions therefrom and additions thereto as are permitted or required by Form&nbsp;F-10 and the Securities
Act, relating to the offering of the Shares, to be filed by the Company with the Commission pursuant to General Instruction II.L of Form&nbsp;F-10;
 &ldquo;<U>U.S. Prospectus</U>&rdquo; means the U.S. Prospectus Supplement (and any additional U.S. Prospectus Supplement prepared in
accordance with the provisions of this Agreement and filed with the Commission in accordance with General Instruction II.L of Form&nbsp;F-10)
together with the U.S. Base Prospectus; &ldquo;<U>Base Prospectuses</U>&rdquo; means, collectively, the Canadian Base Prospectus and
the U.S. Base Prospectus; &ldquo;<U>Prospectuses</U>&rdquo; means, collectively, the Canadian Prospectus and the U.S. Prospectus; &ldquo;<U>Prospectus
Supplements</U>&rdquo; means, collectively, the Canadian Prospectus Supplement and the U.S. Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any reference herein to the
Registration Statement, the Base Prospectuses, the Prospectus Supplements or the Prospectuses or any amendment or supplement thereto
shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms &ldquo;amend,&rdquo;
 &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement, the Base Prospectuses, the Prospectus
Supplements or the Prospectuses shall be deemed to refer to and include the filing or furnishing of any document with or to the Commission
or Canadian Qualifying Authorities, as applicable, on or after the effective date of the Registration Statement or the date of the Base
Prospectuses, the Prospectus Supplements or the Prospectuses, as the case may be, and deemed to be incorporated by reference therein.
For purposes of this Agreement, all references to the Canadian Base Prospectus, the Canadian Prospectus Supplement and the Canadian Prospectus
or any amendment or supplement thereto shall be deemed to include any copy filed with any Canadian Qualifying Jurisdiction pursuant to
SEDAR+ and all references to the Registration Statement, the U.S. Base Prospectus, the U.S. Prospectus Supplement and the U.S. Prospectus
or any amendment or supplement thereto shall be deemed to include any copy filed with the Commission pursuant to the Commission&rsquo;s
Electronic Data Gathering Analysis and Retrieval System (&ldquo;<U>EDGAR</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has also previously
prepared and filed with the Commission an appointment of agent for service of process upon the Company on Form&nbsp;F-X in conjunction
with the filing of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to financial statements and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo;
in the Registration Statement, the U.S. Base Prospectus or the U.S. Prospectus (or other references of like import) shall be deemed to
mean and include all such financial statements and schedules and other information which is incorporated by reference in or otherwise
deemed by the Rules&nbsp;and Regulations to be a part of or included in the Registration Statement, the U.S. Base Prospectus or the U.S.
Prospectus, as the case may be; and all references in this Agreement to amendments or supplements to the Registration Statement, the
U.S. Base Prospectus or the U.S. Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange
Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and which is deemed to be incorporated therein by reference or otherwise
deemed by the Rules&nbsp;and Regulations to be a part of or included in the Registration Statement, the U.S. Base Prospectus, and/or
the U.S. Prospectus, as the case may be. All references in this Agreement to financial statements and other information which is &ldquo;described,&rdquo;
 &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo; in the Canadian Base Prospectus or the Canadian Prospectus (or
other references of like import) shall be deemed to mean and include all such financial statements and other information which is incorporated
by reference in or otherwise deemed by Canadian Securities Laws to be a part of or included in the Canadian Base Prospectus or Canadian
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company confirms its
agreement with the Agents as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sale
and Delivery of the Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Agency
Transactions</I>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions
herein set forth, the Company and the Agents agree that the Company may issue and sell through the Agents, as sales agents for the Company,
the Shares (an &ldquo;<U>Agency Transaction</U>&rdquo;) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company may, from time to time, propose to the applicable Agent the terms of an Agency Transaction by means of a telephone call or form
of written electronic communication (confirmed promptly by electronic mail in a form substantially similar to <U>Exhibit&nbsp;A</U> hereto
(an &ldquo;<U>Agency Transaction Notice</U>&rdquo;)) from at least one of the individuals listed as an authorized representative of the
Company on <U>Schedule 1</U> hereto (each, an &ldquo;<U>Authorized Company Representative</U>&rdquo;), such proposal to include, among
other parameters permitted in accordance with this Agreement: the trading day(s)&nbsp;for the Nasdaq Stock Market LLC (the &ldquo;<U>Nasdaq</U>&rdquo;)
or the Toronto Stock Exchange (the &ldquo;<U>TSX</U>&rdquo;) (which may not be a day on which the Nasdaq or the TSX, as applicable, is
closed or scheduled to close prior to its regular weekday closing time) on which the Shares are to be sold (each, a &ldquo;<U>Trading
Day</U>&rdquo;); the maximum number or value of Shares that the Company wishes to sell in the aggregate and any limitation on the number
or value of Shares that may be sold in any one Trading Day; the minimum price at which the Company is willing to sell the Shares (the
 &ldquo;<U>Floor Price</U>&rdquo;); and the Placement Fee (as defined herein). The Agency Transaction Notice shall be effective upon delivery
to the applicable Agent unless and until (A)&nbsp;the applicable Agent declines to accept the terms contained therein and does not confirm
promptly in accordance with Section&nbsp;1(a)(ii), (B)&nbsp;the entire amount of the Shares under the Agency Transaction Notice have
been sold, (C)&nbsp;the Company suspends or terminates the Agency Transaction Notice in accordance with the notice requirements set forth
in Section&nbsp;1(a)(iv)&nbsp;or Section&nbsp;7, as applicable, (D)&nbsp;the Company issues a subsequent Agency Transaction Notice with
parameters superseding those on the earlier Agency Transaction Notice, or (E)&nbsp;this Agreement has been terminated or suspended under
the provisions of this Agreement. The terms of an Agency Transaction shall be proposed to, and each Agency Transaction Notice shall be
addressed to, the respective individuals from the applicable Agent set forth on <U>Schedule 1</U> hereto (the &ldquo;<U>Authorized Agent
Representatives</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
such proposed terms for an Agency Transaction are acceptable to the applicable Agent, it shall promptly confirm the terms by countersigning
the Agency Transaction Notice for such Agency Transaction and emailing it to the Authorized Company Representatives which delivered such
Agency Transaction Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to the terms and conditions hereof, the applicable Agent shall, severally and not jointly, use its commercially reasonable efforts to
sell all of the Shares designated in, and subject to the terms of, such Agency Transaction Notice. The applicable Agent shall not sell
any Share at a price lower than the Floor Price. The Company acknowledges and agrees with the Agents that (x)&nbsp;there can be no assurance
that an Agent will be successful in selling all or any of such Shares or as to the price at which any Shares are sold, if at all, (y)&nbsp;no
Agent shall incur any liability or obligation to the Company or any other person or entity if they do not sell any Shares for any reason
and (z)&nbsp;no Agent shall be under any obligation to purchase any Shares on a principal basis pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company may, acting through at least one Authorized Company Representative, or the applicable Agent may, upon notice to the other party
hereto by telephone (confirmed promptly by electronic mail), suspend an offering of the Shares or terminate an Agency Transaction Notice;
<I>provided</I>, <I>however</I>, that such suspension or termination shall not affect or impair the parties&rsquo; respective obligations
with respect to the Shares sold hereunder prior to the giving of such notice, including the parties&rsquo; obligations set forth under
Section&nbsp;1(a)(viii). Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession
of material non-public information with respect to the Company or the Shares, the Company agrees that (i)&nbsp;it will not deliver an
Agency Transaction Notice to any Agent and (ii)&nbsp;it will terminate any Agency Transaction Notice that was previously delivered to
any Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the terms of any Agency Transaction as set forth in an Agency Transaction Notice contemplate that the Shares shall be sold on more than
one Trading Day, then the Company and the applicable Agent shall mutually agree to such additional terms and conditions as they deem
necessary in respect of such multiple Trading Days, and such additional terms and conditions shall be binding to the same extent as any
other terms contained in the relevant Agency Transaction Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
applicable Agent, as sales agent in an Agency Transaction, shall not make any sales of the Shares on behalf of the Company, pursuant
to this Agreement, other than (x)&nbsp;by means of ordinary brokers&rsquo; transactions that qualify for delivery of the
Prospectuses in accordance with Rule&nbsp;153 of the Rules&nbsp;and Regulations and meet the definition of an &ldquo;at-the-market
offering&rdquo; under Rule&nbsp;415(a)(4)&nbsp;of the Rules&nbsp;and Regulations and an &ldquo;at-the-market-distribution&rdquo;
under NI 44-102 and are made in compliance with NI 44-102, including, without limitation, sales made directly on the Nasdaq and the
TSX, or any Canadian marketplace or United States marketplace or (y)&nbsp;such other sales of the Shares on behalf of the Company in
its capacity as agent of the Company as shall be agreed by the Company and the applicable Agent in writing. Each of the Agents shall
not engage in any transactions in connection with the distribution of Shares in this &ldquo;at-the-market&rdquo; distribution that
are intended to stabilize or maintain the market price of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
compensation to each Agent for sales of the Shares in an Agency Transaction with respect to which such Agent acts as sales agent hereunder
shall be as set forth in the Agency Transaction Notice for such Agency Transaction but shall not exceed three percent (3%) of the gross
offering proceeds of the Shares sold in such Agency Transaction (the &ldquo;<U>Placement Fee</U>&rdquo;). The applicable Agent shall
provide written confirmation to the Company (which may be provided by email to at least one of the Authorized Company Representatives)
following the close of trading on each Trading Day on which Shares are sold in an Agency Transaction under this Agreement, setting forth
(i)&nbsp;the number of Shares and the average price of Shares sold on such Trading Day (showing the number and the average price of Shares
sold on the TSX, on the Nasdaq or on any other &ldquo;marketplace&rdquo;), (ii)&nbsp;the gross offering proceeds received from such sales,
(iii)&nbsp;the Placement Fee payable by the Company to such Agent with respect to such sales (which Placement Fee shall be paid in the
same currency as the sale of the Shares to which such Placement Fee pertains) and (iv)&nbsp;the net offering proceeds (being the gross
offering proceeds for such sales less the Placement Fee payable for such sales) (the &ldquo;<U>Net Offering Proceeds</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Settlement
for sales of the Shares in an Agency Transaction pursuant to this Agreement shall occur on the second Trading Day (or such earlier
day as is industry practice for regular-way trading) following the date on which such sales are made (each such day, a
 &ldquo;<U>Settlement Date</U>&rdquo;). On each Settlement Date, the Shares sold through the applicable Agent in Agency Transactions
for settlement on such date shall be issued and delivered by the Company to the applicable Agent against payment by the applicable
Agent to the Company of the Net Offering Proceeds from the sale of such Shares. Settlement for all such Shares shall be effected by
free delivery of the Shares by the Company or its transfer agent to the applicable Agent&rsquo;s or its designee&rsquo;s account
(<I>provided</I> that the applicable Agent shall have given the Company written notice of such designee prior to the relevant
Settlement Date) through the facilities of CDS Clearing and Depository Services Inc. through its &ldquo;CDSX&rdquo; system or The
Depository Trust Company or by such other means of delivery as may be mutually agreed upon by the parties hereto, which in all cases
shall be freely tradable, transferable, registered shares in good deliverable form, in return for payment in same-day funds
delivered to the account designated by the Company. If the Company, or its transfer agent (if applicable), shall default on its
obligation to deliver the Shares on any Settlement Date, the Company shall (i) hold the applicable Agent harmless against any loss,
claim, damage, or expense (including, without limitation, reasonable legal fees and expenses), as incurred, arising out of or in
connection with such default by the Company and (ii) pay the applicable Agent any commission, discount or other compensation to which it would otherwise be entitled absent such default,
including the Placement Fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Maximum
Number of Shares</I>. Under no circumstances shall the Company propose to any one of the Agents, or any one of the Agents effect, a sale
of Shares in an Agency Transaction pursuant to this Agreement if such sale would (i)&nbsp;cause the aggregate gross sales proceeds of
the Shares sold pursuant to this Agreement to exceed the Maximum Amount, (ii)&nbsp;cause the number of Shares sold to exceed the number
of Common Shares available for offer and sale under the then effective Canadian Prospectus or Registration Statement, or (iii)&nbsp;cause
the number of Shares sold pursuant to this Agreement to exceed the number of Shares authorized to be issued and sold from time to time
pursuant to this Agreement by the Company&rsquo;s board of directors, or a duly authorized committee thereof, and notified to the applicable
Agent in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Market
Activities</I>. The Company will not, directly or indirectly, (i)&nbsp;take any action designed to cause or result in, or that constitutes
or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Shares or (ii)&nbsp;sell, bid for, or purchase the Shares in violation of Regulation M, or pay anyone any compensation
for soliciting purchases of the Shares other than the Agents. The applicable Agent, shall not make any sales of the Shares on behalf
of the Company, pursuant to this Agreement, other than by means of ordinary brokers&rsquo; transactions (x)&nbsp;that qualify for delivery
of the Prospectuses in accordance with Rule&nbsp;153 of the Rules&nbsp;and Regulations, (y)&nbsp;that constitute an &ldquo;at-the-market-distribution&rdquo;
under NI 44-102 and are made in compliance with NI 44-102, including, without limitation, sales made directly on the Nasdaq and the TSX
or any Canadian marketplace or United States marketplace or (z)&nbsp;such other sales of the Shares on behalf of the Company in its capacity
as agent of the Company as shall be agreed by the Company and the applicable Agent in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Black-out
Periods</I>. Notwithstanding any other provision of this Agreement, during any other period in which the Company is in possession of
material non-public information with respect to the Company or the Shares, the Company and the applicable Agent (provided that the Agent
has been given prior written notice of such by the Company, which notice the Agent agrees to treat confidentially) agree that no sales
of Shares shall take place, the Company shall not request the sales of any Shares, and the Agents shall not be obligated to sell or offer
to sell any Shares. The Company and the Agents agree that no such notice shall be effective against any other party unless it is made
to one of the individuals named on <U>Schedule 1</U> hereto, as such <U>Schedule 1</U> may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Continuing
Accuracy of Representations and Warranties</I>. Any obligation of the Agents to use their commercially reasonable efforts to sell the
Shares on behalf of the Company as sales agents shall be subject to the continuing accuracy of the representations and warranties of
the Company herein, to the performance by the Company of its obligations hereunder and to the continuing satisfaction of the conditions
specified in Section&nbsp;4 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. The Company represents and warrants to, and covenants with, the Agents as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Registration
Statement and Prospectus</I>. The Company is qualified in accordance with the provisions of NI 44-101 and NI 44-102 to file a short form
base shelf prospectus in each of the Canadian Qualifying Jurisdictions and the entering into of this Agreement will not cause the Receipt
to no longer be effective. The Registration Statement has become effective pursuant to Rule&nbsp;467(b)&nbsp;under the Securities Act;
no stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose are pending
before or, to the Company&rsquo;s knowledge, threatened by the Commission and the Receipt has been obtained from the Reviewing Authority
in respect of the Canadian Base Prospectus. No order or action that would have the effect of ceasing or suspending the distribution of
the Shares or any other securities of the Company has been issued by the Canadian Qualifying Authorities or any similar regulatory authority,
and no proceedings for such purpose are pending before or, to the Company&rsquo;s knowledge, threatened; and any request made to the
Company on the part of any Canadian Qualifying Authorities for additional information has been complied with in all material respects.
The Canadian Prospectus, at the time of filing thereof with the Canadian Qualifying Authorities, complied in all material respects and,
as amended or supplemented, if applicable, will comply in all material respects with Canadian Securities Laws; the Canadian Prospectus,
as amended or supplemented, as of its date, did not, and as of each Time of Sale (as defined herein) and Settlement Date, if any, will
not contain a misrepresentation, as defined under Canadian Securities Laws; and the Canadian Prospectus, as amended or supplemented,
as of its date, did and, as of each Time of Sale and Settlement Date, if any, will constitute, full, true and plain disclosure of all
material facts relating to the Shares and to the Company. All forward-looking information (as defined in National Instrument 51-102 <I>Continuous
Disclosure Obligations</I> (&ldquo;<U>NI 51-102</U>&rdquo;)) and statements of the Company contained in the Registration Statement and
the Prospectuses and the assumptions underlying such information and statements, subject to any qualifications contained therein, including
any forecasts and estimates, expressions of opinion, intention and expectation, as at the time they were or will be made, were or will
be made on reasonable grounds after due and proper consideration and were or will be truly and honestly held and fairly based. &ldquo;<U>Time
of Sale</U>&rdquo; means the time of the applicable Agent&rsquo;s initial entry into contracts with investors for the sale of such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Accurate
Disclosure</I>. (i)&nbsp;Each document, if any, filed, furnished, or delivered, or to be filed, furnished, or delivered, pursuant to
(A)&nbsp;Canadian Securities Laws and incorporated by reference in the Canadian Prospectus complied or will comply when so filed in all
material respects with Canadian Securities Laws and (B)&nbsp;the Exchange Act and incorporated by reference in the Registration Statement,
the Prospectuses and the Disclosure Package complied or will comply when so filed in all material respects with the Exchange Act and
the applicable rules&nbsp;and regulations of the Commission thereunder, (ii)&nbsp;each part of the Registration Statement, when such
part became effective, did not contain, and each such part, as amended or supplemented, if applicable, will not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
(iii)&nbsp;the Registration Statement as of the date hereof does not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading, (iv)&nbsp;the Registration
Statement and the U.S. Prospectus comply, and as amended or supplemented, if applicable, and the applicable Permitted Free Writing Prospectus(es),
if any, issued at or prior to such Time of Sale, taken together (collectively, and with respect to any Shares, together with the public
offering price of such Shares, the &ldquo;<U>Disclosure Package</U>&rdquo;) and at each Time of Sale and Settlement Date, will comply
in all material respects with the Securities Act and the applicable rules&nbsp;and regulations of the Commission thereunder, (v)&nbsp;the
Disclosure Package does not and at the time of each sale of the Shares in connection with the offering when the Prospectuses are not
yet available to prospective purchasers and at any Time of Sale and Settlement Date, the Disclosure Package, as then amended or supplemented
by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading, (vi)&nbsp;each broadly available
road show, if any, when considered together with the Disclosure Package, does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading, and (vii)&nbsp;the U.S. Prospectus does not contain and, as amended or supplemented, if applicable, will not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. All statistical or market-related data included in the Registration Statement,
the Prospectuses and the Disclosure Package comply, are based on or derived from sources that the Company believes to be reliable and
accurate in all material respects, and the Company has obtained the written consent to the use of such data from such sources to the
extent required. The Form&nbsp;F-X conforms with the requirements of the Securities Act and the applicable rules&nbsp;and regulations
of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The representations and warranties in this
subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the Disclosure
Package or the Prospectuses (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance upon and in
conformity with written information furnished to the Company by any Agent through the Authorized Company Representative expressly
for use therein. For purposes of this Agreement, the only information so furnished shall be the names of the Agents set forth on the
front and back covers and on the certificate of the Agents in the Prospectus Supplements (collectively, the &ldquo;<U>Agent
Information</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Permitted
Free Writing Prospectus</I>. No Permitted Free Writing Prospectus (as defined herein) conflicts or will conflict with the information
contained in the Registration Statement, the Prospectuses and the Disclosure Package, and any preliminary or other prospectus deemed
to be a part thereof that has not been superseded or modified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Company
Not Ineligible Issuer</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest
time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;of
the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined
in Rule&nbsp;405 under the Securities Act, without taking account of any determination by the Commission pursuant to Rule&nbsp;405 under
the Securities Act that it is not necessary that the Company be considered an ineligible issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Emerging
Growth Company Status</I>. The Company is an &ldquo;emerging growth company,&rdquo; as defined in Section&nbsp;2(a)&nbsp;of the Securities
Act (an &ldquo;<U>Emerging Growth Company</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Independent
Accountants</I>. The accountants who certified the financial statements and supporting schedules included or incorporated by reference
in the Registration Statement, the Prospectuses and the Disclosure Package are (i)&nbsp;independent public accountants as required by
the Securities Act and the Public Company Accounting Oversight Board, and (ii)&nbsp;independent with respect to the Company as required
by applicable Canadian professional standards; and in the period of three years prior to the date hereof, there has not been any reportable
event (within the meaning of NI 51-102) between the Company and such accountants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Audit
Committee</I>. The Company has a validly appointed audit committee whose composition and responsibilities satisfy the requirements of
Section&nbsp;10A of, and Rule&nbsp;10A-3 under, the Exchange Act and National Instrument 52-110 <I>Audit Committees</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Financial
Statements</I>. The financial statements included or incorporated by reference in the Registration Statement, the Prospectuses and the
Disclosure Package, together with the related schedules and notes, present fairly, in all material respects, the financial position of
the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, shareholders&rsquo; equity and
cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been prepared in
conformity with International Financial Reporting Standards, as issued by the International Accounting Standards Board (&ldquo;<U>IFRS</U>&rdquo;)
applied on a consistent basis throughout the periods involved. Except as included or incorporated by reference therein, no historical
or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration
Statement, the Prospectuses and the Disclosure Package under the Securities Act or Canadian Securities Laws. There has been no change
in accounting policies or practices of the Company since January&nbsp;1, 2023 except as disclosed in the financial statements included
or incorporated by reference in the Registration Statement, the Prospectuses and the Disclosure Package. No other financial statements,
schedules or reconciliations of &ldquo;non-IFRS financial measures&rdquo; of the Company are required by applicable securities laws to
be included in the Registration Statement, the Prospectuses and the Disclosure Package.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Material
Liabilities</I>. Except as set out in the financial statements included or incorporated by reference in the Registration Statement, the
Prospectuses and the Disclosure Package or as incurred in the ordinary course of business since June&nbsp;30, 2023 and as would not individually
or in the aggregate have a Material Adverse Effect, the Company does not have any outstanding indebtedness or any liabilities or obligations
including any unfunded obligation under any employee plan, whether accrued, absolute, contingent or otherwise as of the date of the applicable
financial statements. The term &ldquo;<U>Material Adverse Effect</U>&rdquo; means an effect, change, event or occurrence that, alone
or in conjunction with any other or others: (i)&nbsp;has or would reasonably be expected to have a material adverse effect on the business,
assets (including intangible assets), affairs, operations, prospects, liabilities (contingent or otherwise), capital, properties, condition
(financial or otherwise) or results of operations of the Company and its subsidiaries, on a consolidated basis, whether or not arising
in the ordinary course of business, or (ii)&nbsp;would result in the Canadian Prospectus or any amendment or supplement thereto containing
a misrepresentation within the meaning of applicable Canadian Securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Sarbanes-Oxley
Act of 2002</I>. The Company is, and after giving effect to the offering and sale of the Shares will be, in compliance in all material
respects with all applicable effective provisions of the Sarbanes-Oxley Act of 2002 and the rules&nbsp;and regulations promulgated in
connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>No
Material Adverse Change in Business</I>. Except as otherwise stated therein in the Registration Statement, the Prospectuses and the Disclosure
Package, since June&nbsp;30, 2023, (A)&nbsp;there has been no material adverse change, whether actual, anticipated, contemplated, or
to the knowledge of the Company, threatened or proposed, in the business, assets (including intangible assets), affairs, operations,
prospects, liabilities (contingent or otherwise), capital, properties, condition (financial or otherwise) or results of operations of
the Company and its subsidiaries, on a consolidated basis, whether or not arising in the ordinary course of business (a &ldquo;<U>Material
Adverse Change</U>&rdquo;), (B)&nbsp;there have been no transactions entered into by the Company or its subsidiaries, other than those
in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise,
(C)&nbsp;there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its securities,
and (D)&nbsp;neither Company nor any of its subsidiaries has incurred any obligation or liability, direct or indirect, contingent or
otherwise, except in the ordinary course of business and which is not, and which in the aggregate are not, material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Good
Standing of the Company</I>. The Company has been duly organized and is validly existing as a corporation in good standing under the
laws of the Province of Ontario and has corporate power, capacity and authority to own, lease and operate its properties and to conduct
its business as described in the Registration Statement, the Prospectuses and the Disclosure Package and to enter into and perform its
obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing
in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the
conduct of business. Neither the Company nor, to the knowledge of the Company, any other person, has taken any steps or proceedings,
voluntary or otherwise, requiring or authorizing the Company&rsquo;s dissolution or winding up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Subsidiaries</I>.
The Company does not own, directly or indirectly, any shares of stock or any other equity or long-term debt securities of any corporation
or have any equity interest in any corporation, firm, partnership, joint venture, association or other entity, other than those identified
in the Registration Statement and the Prospectuses. Each subsidiary of the Company  has been duly incorporated, is validly existing and
in good standing under the laws of the jurisdiction of its formation, has the corporate or other similar power and capacity to own its
property and to conduct its business as described in the Registration Statement, the Prospectuses and the Disclosure Package and is duly
qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or
leasing of property requires such qualification. The Company is the direct or indirect registered and beneficial owner of all of the
issued and outstanding shares and other voting securities of each of its subsidiaries, free and clear of all encumbrances, liens, mortgages,
hypothecations, security interests, charges or adverse interests whatsoever. None of the Company&rsquo;s subsidiaries nor, to the knowledge
of the Company, any other person, has taken any steps or proceedings, voluntary or otherwise, requiring or authorizing such subsidiaries&rsquo;
dissolution or winding up. Except as disclosed in the Registration Statement, the Prospectuses and the Disclosure Package, no subsidiary of the Company is prohibited or restricted,
directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&rsquo;s
equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become
due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to
any other subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Capitalization</I>.
The authorized, issued and outstanding share capital of the Company is as set forth in the Registration Statement, the Prospectuses and
the Disclosure Package under the caption &ldquo;Consolidated Capitalization&rdquo; (except for subsequent issuances, if any, (A)&nbsp;pursuant
to this Agreement, (B)&nbsp;pursuant to reservations, agreements or employee benefit plans referred to in the Registration Statement,
the Prospectuses and the Disclosure Package or (C)&nbsp;pursuant to the exercise of convertible securities or options referred to in
the Registration Statement, the Prospectuses and the Disclosure Package). The outstanding shares in the capital of the Company have been
duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares in the capital of the Company
were issued in violation of the pre-emptive or other similar rights of any securityholder of the Company or other person. No person,
firm, corporation or entity has any agreement, option, right or privilege (whether pre-emptive or contractual) capable of becoming an
agreement or option, for the purchase from the Company or any of its subsidiaries of any of the shares or other securities of the Company
or any such subsidiary, or to require the Company or any of its subsidiaries to purchase, redeem or otherwise acquire any of the outstanding
securities in the share capital of the Company or any of its subsidiaries. To the knowledge of the Company, no agreement is in force
or effect which in any manner affects the voting or control of any of the securities of the Company or any of its subsidiaries. The form
and terms of the certificate representing the Common Shares have been approved and adopted by the board of directors of the Company and
the form and terms of the certificate representing the Common Shares do not and will not conflict with any applicable laws or the rules&nbsp;and
by-laws of the Nasdaq and TSX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Authorization
of Agreement</I>. This Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Authorization
and Description of Securities</I>. The Shares have been duly authorized for issuance and sale and, when issued and delivered by the Company,
will be validly issued and fully paid and non-assessable; and, the issuance of the Shares is not subject to the pre-emptive or other
similar rights of any securityholder of the Company or other person, other than as disclosed to the Agents and in respect of which enforceable
waivers have been received by the Company. The Common Shares conform, in all material respects, to all statements relating thereto contained
in the Registration Statement, the Prospectuses and the Disclosure Package and such description conforms to the rights set forth in the
instruments defining the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Registration
Rights</I>. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant
to the Registration Statement or otherwise registered for sale or sold by the Company in the manner set forth in the Prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Absence
of Violations, Defaults and Conflicts</I>. Except as has been disclosed in the Prospectuses, neither the Company nor its subsidiaries
is (A)&nbsp;in violation of its charter, by-laws or similar organizational document, (B)&nbsp;in default in the performance or observance
of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement,
note, lease or other agreement or instrument to which the Company or its subsidiaries is a party or by which either of them may be bound
or to which any of the properties or assets of the Company or any subsidiary is subject (collectively, &ldquo;<U>Applicable Agreements</U>&rdquo;),
or (C)&nbsp;in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental
body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or its subsidiaries
or any of their respective properties, assets or operations (each, a &ldquo;<U>Governmental Authority</U>&rdquo;), except, in the case
of (B)&nbsp;or (C), for such default or violations that would not, singly or in the aggregate, result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The execution, delivery and
performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the Prospectuses
and the Disclosure Package (including the issuance and sale of the Shares at any Time of Sale and Settlement Date, as applicable,) have
been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice or passage
of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation
or imposition of any lien, security interest, charge or encumbrance upon any properties or assets of the Company or its subsidiaries
pursuant to, the Applicable Agreements (except for such conflicts, breaches, defaults or Repayment Events or liens, security interests,
charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result
in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or its subsidiaries or any
law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Authority. As used herein, a &ldquo;<U>Repayment
Event</U>&rdquo; means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any
person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such
indebtedness by the Company or its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Listing</I>.
The Common Shares are listed on the Nasdaq and the TSX, and the Shares will be listed and posted for trading on the Nasdaq and the TSX
at the Time of Sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Absence
of Labor Dispute</I>. No labor dispute with the employees of the Company or its subsidiaries exists or, to the knowledge of the Company,
is imminent, which would result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries is currently conducting
negotiations with any labor union or employee association. The Company and each of its subsidiaries are in compliance in all material
respects with all laws respecting employment and employment practices, terms and conditions of employment, pay equity and wages and have
not and are not engaged in any unfair labor practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Benefit
Plans</I>. Other than the Victor Insurance Benefit Plan, United Healthcare and Principal Benefit Plan and the Long Term Incentive Plan
of the Company dated May&nbsp;20, 2020, and as otherwise as disclosed in the Registration Statement, the Prospectuses and the Disclosure
Package, neither the Company nor its subsidiaries have agreements, plans or practices relating to the payment of any management, consulting,
service or other fees or any bonuses, pensions, share of profits or retirement allowance, insurance, health or other employee benefits
or any plan for retirement, stock purchase, profit sharing, stock option, deferred compensation, severance or termination pay, insurance,
medical, hospital, dental, vision care, drug, sick leave, disability, salary continuation, legal benefits, unemployment benefits, vacation,
incentive or otherwise contributed to, or required to be contributed to, by the Company or any of its subsidiaries for the benefit of
any current or former director, officer, employee or consultant of the Company or any of its subsidiaries (&ldquo;<U>Employee Plans</U>&rdquo;).
The Company has made available to the Agents true and complete copies of documents, contracts and arrangements relating to the Employee
Plans. The Employee Plans have been established, operated in the ordinary course and administered in all material respects in accordance
with their terms and applicable laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>ERISA
Compliance</I>. Any &ldquo;<U>Employee Benefit Plan</U>&rdquo; (as defined under the Employee Retirement Income Security Act of 1974,
as amended (&ldquo;<U>ERISA</U>&rdquo;)) established or maintained by the Company and its subsidiaries is in compliance in all material
respects with ERISA. No material &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur
with respect to any Employee Benefit Plan established or maintained by the Company, any of its subsidiaries or any member of any group
of organizations described in Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the
regulations and published interpretations thereunder (the &ldquo;<U>Code</U>&rdquo;) of which the Company or such subsidiary is a member
(an &ldquo;<U>ERISA Affiliate</U>&rdquo;). No Employee Benefit Plan established or maintained by the Company, its subsidiaries or any
of their ERISA Affiliates, if such Employee Benefit Plan were terminated, would have any material &ldquo;amount of unfunded benefit liabilities&rdquo;
(as defined under ERISA). Neither the Company, any of its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects
to incur any material liability under (i)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any Employee Benefit
Plan or (ii)&nbsp;Section&nbsp;412, 4971 or 4975 of the Code. Each Employee Benefit Plan established or maintained by the Company and
its subsidiaries that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified, and nothing has occurred,
whether by action or failure to act, which would reasonably be expected to cause the loss of such qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(w)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Absence
of Proceedings</I>. There is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Authority (including,
without limitation, any action, suit proceeding, inquiry or investigation before or brought by the U.S. Food and Drug Administration
(the &ldquo;<U>FDA</U>&rdquo;)) now pending or, to the knowledge of the Company, threatened, against or affecting the Company or its
subsidiaries, which would reasonably be expected to result in a Material Adverse Effect; and the aggregate of all pending legal or governmental
proceedings to which the Company or any such subsidiaries is a party or of which any of their respective properties or assets is the
subject which are not described in the Registration Statement, the Prospectuses and the Disclosure Package, including ordinary routine
litigation incidental to the business, would not reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Accuracy
of Exhibits</I>. There are no contracts or documents which are required to be described in the Registration Statement, the Prospectuses
or the Disclosure Package or to be filed as exhibits to the Registration Statement which (a)&nbsp;have not been so described and filed
as required or (b)&nbsp;in the case of exhibits to the Registration Statement, will be so filed prior to any Time of Sale and Settlement
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(y)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Absence
of Further Requirements</I>. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree
of, any Governmental Authority is necessary or required for the performance by the Company of its obligations hereunder, in connection
with the offering, issuance or sale of the Shares hereunder or the consummation of the transactions contemplated by this Agreement, except
such as have been already obtained or as may be required under the Securities Act, Canadian Securities Laws, the rules&nbsp;of Nasdaq
or the TSX, state securities laws or the rules&nbsp;of the Financial Industry Regulatory Authority (&ldquo;<U>FINRA</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(z)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>FINRA
Matters</I>. The Company meets the requirements for the exemption from FINRA filing requirements that is available to registrants meeting
the eligibility requirements for use of Form&nbsp;F-10 under the Securities Act specified in FINRA Rule&nbsp;5110(b)(7)(C)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Possession
of Licenses and Permits</I>. The Company and its subsidiaries possess such permits, licenses, approvals, consents and other authorizations
(collectively, &ldquo;<U>Governmental Licenses</U>&rdquo;) issued by the appropriate Governmental Authorities that are material to the
conduct of the business now operated by them. The Company and its subsidiaries are in compliance with the terms and conditions of all
Governmental Licenses and neither the Company nor any of its subsidiaries is in breach thereof or in default with respect to filings
to be effected or conditions to be fulfilled in order to maintain such Governmental Licenses in good standing, except where the failure
so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and
in full force and effect. Neither the Company nor its subsidiaries has received any notice of proceedings relating to the revocation
or modification of any Governmental Licenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(bb)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Title
to Property</I>. The Company and its subsidiaries have good and marketable title to all real property owned by them and good title to
all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions
or encumbrances of any kind except such as (A)&nbsp;are described in the Registration Statement, the Prospectuses and the Disclosure
Package or (B)&nbsp;do not, singly or in the aggregate, materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company or its subsidiaries; and all of the leases and subleases material
to the business of the Company and its subsidiaries, considered as one enterprise, and under which the Company or its subsidiaries holds
properties described in the Registration Statement, the Prospectuses or the Disclosure Package, are in full force and effect, and neither
the Company nor any such subsidiaries has any notice of any material claim of any sort that has been asserted by anyone adverse to the
rights of the Company or any subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights
of the Company or such subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(cc)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Title
to Intellectual Property</I>. The Company and its subsidiaries own or have valid, binding and enforceable licenses or other rights under
the patents, inventions, copyrights, trade secrets, know-how, other proprietary rights in information, systems, devices, procedures,
software, data, and databases, trademarks, service marks, trade names, and applications to any of the foregoing, and licenses to any
of the foregoing, and other intellectual property described in the Registration Statement, the Prospectuses and the Disclosure Package,
and any other such intellectual property which, is necessary for, or used in the conduct, or the proposed conduct, of the business of
the Company and its subsidiaries in the manner described in the Registration Statement, the Prospectuses and the Disclosure Package (collectively,
the &ldquo;<U>Intellectual Property</U>&rdquo;); the patents, trademarks, and copyrights, if any, included within the Intellectual Property
are valid, enforceable, and subsisting, all applications for any of the foregoing are subsisting and in good standing, there are no actions,
suits, proceedings or claims challenging the ownership, validity or enforceability of any of the foregoing, and the Company is not aware
of any facts which would form a reasonable basis for any such actions, suits, proceedings or claims; other than as disclosed in the Registration
Statement, the Prospectuses and the Disclosure Package, (A)&nbsp;the Company is not obligated to pay a material license fee, milestone
fee, or royalty, grant a license or covenant not to sue, or provide other material consideration to any third party in connection with
the Intellectual Property, (B)&nbsp;the Company has not received any notice of any claim of infringement, misappropriation or conflict
with any intellectual property rights of others with respect to any of the Company&rsquo;s systems, devices, software, processes or Intellectual
Property, (C)&nbsp;to the knowledge of the Company, neither the sale nor use of any of the discoveries, inventions, systems, devices,
software, or processes of the Company referred to in the Registration Statement, the Prospectuses or the Disclosure Package do or will,
infringe, misappropriate or violate any intellectual property rights of any third party, and (D)&nbsp;no third party has any ownership
or other right in or to any Intellectual Property that is owned by the Company or any of its subsidiaries (&ldquo;<U>Company Owned IP</U>&rdquo;),
other than non-exclusive licenses to the Company&rsquo;s software granted in the ordinary course of business and any co-owner of any
patent constituting Intellectual Property who is listed on the records of the U.S. Patent and Trademark Office (the &ldquo;<U>USPTO</U>&rdquo;)
and any co-owner of any patent application constituting Intellectual Property who is named in such patent application, except as disclosed
in the Registration Statement, the Prospectuses and the Disclosure Package, all Company Owned IP is free and clear of all liens, security
interests or encumbrances, and, to the knowledge of the Company, no third party has any rights in or to any Intellectual Property in
any field of use that is exclusively licensed to the Company, other than the ownership rights of any licensor (without any reservation
of rights to practice the Intellectual Property in such field of use) to the Company of such Intellectual Property. The Company and its
subsidiaries have taken all reasonable steps to protect, maintain and safeguard the Intellectual Property, including the execution of
appropriate nondisclosure, confidentiality agreements and invention assignments with their employees, consultants or independent contractors,
and no employee, consultant, or independent contractor of the Company is in or has been in violation of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement,
or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s employment
with the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(dd)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>License
Agreements</I>. The Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property
has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect. To the extent that (i)&nbsp;any
of the Intellectual Property that is owned by or exclusively licensed to the Company or any of its subsidiaries is licensed or (ii)&nbsp;any
of the Intellectual Property that is owned by or exclusively licensed to the Company or any of its subsidiaries, and that is treated
by the Company or any of its subsidiaries as confidential, is disclosed, in either case, to any other person by the Company or any of
its subsidiaries, the Company or any of its subsidiaries, as applicable, has entered into a valid and subsisting written agreement with
any such person which contains terms and conditions prohibiting the unauthorized use, disclosure or transfer of such Intellectual Property
by such person. Other than such agreements that have expired in accordance with their respective terms, all such agreements are in full
force and effect and, to the knowledge of the Company, none of the Company, any of its subsidiaries or, any other person, is in material
default or material breach of its obligations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ee)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Patents
and Patent Applications</I>. All patents and patent applications owned by or licensed to the Company or any of its subsidiaries or under
which the Company or any of its subsidiaries has rights and which are necessary and material in the conduct, or proposed conduct, of
the business of the Company and its subsidiaries in the manner described in the Registration Statement, the Prospectuses and the Disclosure
Package have, been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications
have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware
of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent
in connection with any such application or would reasonably be expected to form the basis of a finding of invalidity or unenforceability
with respect to any patents that have issued with respect to such applications. The products and product candidates described in the
Registration Statement, the Prospectuses and the Disclosure Package fall within the scope of the claims of one or more patents or patent
applications owned by, or exclusively licensed to, the Company or any of its subsidiaries. All inventors of patents and patent applications
owned by the Company or any of its subsidiaries have assigned his or her ownership rights in such patents and patent applications to
the Company or any of its subsidiaries and all such assignments have been recorded with the applicable patent office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ff)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>FDA
and Other Legal Compliance</I>. The Company has received clearance from the FDA to market TULSA-PRO in the United States for ablation
of prostate tissue (the &ldquo;<U>FDA TULSA-PRO Clearance</U>&rdquo;), and the Company has received a humanitarian device exemption from
the FDA authorizing the marketing of Sonalleve in the United States for treatment of osteoid osteoma in the extremities (the &ldquo;<U>FDA
Sonalleve Clearance</U>,&rdquo; and together with the FDA TULSA-PRO Clearance, the &ldquo;<U>FDA Clearances</U>&rdquo;). The Company
and its subsidiaries are and at all times have been in material compliance with all statutes, rules&nbsp;or regulations of Regulatory
Authorities applicable to the testing, development, manufacture, packaging, processing, distribution, marketing, labeling, promotion,
sale, offer for sale, storage, import, or export of any medical device product under development, manufactured or distributed by the
Company and its subsidiaries (&ldquo;<U>Applicable Device Laws</U>&rdquo;). The Company and its subsidiaries possess all required licenses,
certificates, approvals, clearances, exemptions, authorizations, permits and any supplements or amendments thereto required by any Applicable
Device Law (together with the FDA Clearances, &ldquo;<U>Authorizations</U>&rdquo;), except where the failure to possess such Authorizations
would not, singly or in the aggregate, result in a Material Adverse Effect, and such Authorizations are valid and in full force and effect.
The Company and its subsidiaries have not received any FDA Form&nbsp;483, notice of adverse finding, warning letter, untitled letter,
or other correspondence or notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
by the FDA, Health Canada, or any other Governmental Authority regulating or otherwise exercising authority with respect to the development,
testing, clinical investigation, manufacture, commercial distribution, sale, import, export or marketing of medical products (collectively,
 &ldquo;<U>Regulatory Authorities</U>&rdquo;) alleging or asserting material noncompliance with any Applicable Devices Laws or the terms
or conditions of any Authorizations. The Company and its subsidiaries have not received notice that any Regulatory Authority has taken,
is taking or intends to take action to materially limit, suspend, modify or revoke any material Authorizations. The Company and its subsidiaries
have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required by any Applicable Device Laws or Authorizations, except where the failure to do so would not, singly
or in the aggregate, result in a Material Adverse Effect, and all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by
a subsequent submission). To the knowledge of the Company, there is no materially false or misleading information or material omission
in any submission made by or on behalf of the Company or any of its subsidiaries to any Regulatory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(gg)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Government
Health Care Programs</I>. To the Company and its subsidiaries&rsquo; knowledge, no persons who have engaged in any activity that is in
violation of, or have been convicted of, charged with, or investigated for, a felony or a criminal offense under any applicable laws,
who are excluded, suspended, debarred, prohibited from providing services under, or otherwise ineligible to participate in any Government
Health Care Program (as defined below), who have been notified that they are or may be subject to potential exclusion, debarment or other
prohibition from participating in any Government Health Care Program, or who have committed any act or have engaged in any activity that
is permissive or mandatory grounds for exclusion, debarment, suspension, or other ineligibility to so participate, are either employed
by, under contract with, or agents of the Company or any of its subsidiaries or provide items or services on behalf of the Company or
any of its subsidiaries. &ldquo;<U>Government Health Care Program</U>&rdquo; means any federal, provincial, state or other publicly funded
healthcare insurance or reimbursement program, including but not limited to a federal healthcare program as defined in Section&nbsp;1128B(f)&nbsp;of
the United States Federal Social Security Act and includes the United States Medicare, Medicaid and TRICARE programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(hh)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Privacy
Laws</I>. Neither the Company nor any of its subsidiaries has unlawfully disclosed the protected health information of any person, nor
committed any other breach of applicable laws concerning the privacy and/or security of personal health information; nor, to the knowledge
of the Company, is there any investigation of the Company or any of its subsidiaries by any Governmental Authority for a violation of
applicable laws concerning the privacy and/or security of personal health information. Neither the Company nor any of its subsidiaries
has notified, either voluntarily or as required by applicable laws, any affected individual, any Governmental Authority or the media
of any breach of protected health information. To the knowledge of the Company, neither the Company nor any of its subsidiaries has suffered
any unauthorized acquisition, access, use or disclosure of any personal information that, individually or in the aggregate, materially
compromises the security or privacy of such personal information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Facilities</I>.
The Company and its subsidiaries&rsquo; facilities and manufacturing and product research and development activities are and have been
in compliance in all material respects with Applicable Device Laws, including current good manufacturing practice and quality systems
requirements of applicable Regulatory Authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(jj)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Suppliers
and Customers</I>. No material supplier or customer of the Company has cancelled, materially modified, threatened to materially modify
or, to the knowledge of the Company, intends to materially modify its relationship with or supplies to the Company, except any such cancellation,
modification, or threatened modification which would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(kk)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Environmental
Laws</I>. Except as such would not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;neither the Company nor
its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of
common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree
or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface
water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the
release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum
products, asbestos-containing materials or mold that are applicable to their businesses (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;)
or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
 &ldquo;<U>Environmental Laws</U>&rdquo;), (B)&nbsp;the Company and its subsidiaries have all permits, authorizations and approvals required
under any applicable Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or, to the
knowledge of the Company threatened, administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices
of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or its subsidiaries
and (D)&nbsp;there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation,
or an action, suit or proceeding by any private party or Governmental Authority, against or affecting the Company or its subsidiaries
relating to Hazardous Materials or any Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ll)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Accounting
Controls</I>. The Company and its subsidiaries maintain effective internal control over financial reporting (as defined under Rule&nbsp;13-a15
and Rule&nbsp;15d-15 under the Exchange Act) and have established &ldquo;disclosure controls and procedures&rdquo; and &ldquo;internal
control over financial reporting&rdquo; within the meaning of such terms under National Instrument 52-109 <I>Certification of Disclosure
in Issuers&rsquo; Annual and Interim Filings</I> and are in compliance with the certification requirements thereof with respect to the
Company&rsquo;s annual and interim filings with the Canadian Qualifying Authorities. The Company maintains a system of internal accounting
controls sufficient to provide reasonable assurances that (A)&nbsp;transactions are executed in accordance with management&rsquo;s general
or specific authorization; (B)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity
with IFRS and to maintain accountability for assets; (C)&nbsp;access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization; and (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement, the Prospectuses
and the Disclosure Package, since the end of the Company&rsquo;s most recent audited fiscal year, there has been (1)&nbsp;no material
weakness in the Company&rsquo;s internal control over financial reporting (whether or not remediated) and (2)&nbsp;no change in the Company&rsquo;s
internal control over financial reporting that has materially adversely affected, or is reasonably likely to materially adversely affect,
the Company&rsquo;s internal control over financial reporting. The Company is not aware of (x)&nbsp;any significant deficiency in the
design or operation of its internal control over financial reporting which is reasonably likely to adversely affect the Company&rsquo;s
ability to record, process, summarize and report financial data or any material weaknesses in its internal controls, except as disclosed
in the Registration Statement, the Prospectuses and the Disclosure Package, since the end of the Company&rsquo;s most recent audited
fiscal year; or (y)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role
in the Company&rsquo;s internal controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(mm)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Tests
and Preclinical and Clinical Trials</I>. The tests, preclinical studies and clinical trials conducted by or, to the Company&rsquo;s knowledge,
on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols,
procedures and controls pursuant to accepted professional scientific standards and all applicable Authorizations and Applicable Device
Laws, including, as applicable, without limitation, the Federal Food, Drug and Cosmetic Act and the rules&nbsp;and regulations promulgated
thereunder. The descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Prospectuses
and the Disclosure Package are, to the Company&rsquo;s knowledge, accurate and complete in all material respects and fairly present the
data derived from such studies, tests and trials. The Company is not aware of any studies, tests or trials, the results of which the
Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement,
the Prospectuses and the Disclosure Package when viewed in the context in which such results are described and the clinical state of
development; and, the Company has not received any notices or correspondence from any Regulatory Authority requiring the termination
or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course
communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications
have been made available to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(nn)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Payment
of Taxes</I>. All federal, state, local, provincial and foreign income tax returns of the Company and its subsidiaries required by law
to be filed have been filed (in Canada, the United States and otherwise) and all taxes shown by such returns or otherwise assessed, which
are due and payable, have been paid (except for any failure to so pay that would be immaterial), except assessments against which appeals
have been or will be promptly taken and as to which adequate reserves have been provided. All tax returns, declarations, remittances
and filings required to be filed by the Company and its subsidiaries have been filed with all appropriate Governmental Authorities, all
such returns, declarations, remittances and filings are complete and accurate in all material respects and no material fact or facts
have been omitted therefrom which would make any of them misleading and no assessment in connection therewith has been made against the
Company or any of its subsidiaries. To the knowledge of the Company, there are no issues or disputes outstanding with any Governmental
Authority respecting any taxes that have been paid, or may be payable, by the Company or any of its subsidiaries. There are no agreements,
waivers or other arrangements with any taxation authority providing for an extension of time for any assessment or reassessment of taxes
with respect to the Company or any of its subsidiaries. The Company and its subsidiaries have each established on their books and records
reserves that are adequate for the payment of all taxes not yet due and payable and there are no liens for taxes on the assets and properties
of the Company or any of its subsidiaries (other than liens for taxes that are not yet due and payable or that are being contested in
good faith), and, to the knowledge of the Company, there are no audits pending of the tax returns of the Company or any of its subsidiaries
(whether federal, state, provincial, local or foreign) and there are no claims which have been asserted relating to any such tax returns,
which audits and claims, if determined adversely, would result in the assertion by any governmental agency of any material deficiency.
The Company and its subsidiaries have paid all sales and use taxes and all taxes which the Company or any subsidiary is obligated to
withhold from amounts owed to employees, creditors, and third parties. All scientific research and experimental development (&ldquo;<U>SR&amp;ED</U>&rdquo;)
tax incentives applied for by the Company or any of its subsidiaries are bona fide and the Company has no knowledge that Canada Revenue
Agency will disallow, reassess or reduce any SR&amp;ED incentives applied for by or previously granted to the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(oo)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Insurance</I>.
The Company and its subsidiaries carry or are entitled to the benefits of insurance, with reputable insurers, in such amounts and covering
such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance
is in full force and effect. Neither the Company nor any of its subsidiaries is in default in any respect with respect to the payment
of any premium or compliance with any of the provisions contained in any such insurance policy and has not failed to give any notice
or present any claim within the appropriate time therefor. There are no circumstances under which the Company or any of its subsidiaries
would be required to or, in order to maintain its coverage, to give any notice to the insurers under any such insurance policy which
has not been given. Neither the Company nor any of its subsidiaries has received notice from any of the insurers regarding cancellation
of such insurance policy or has been denied any insurance coverage which it has sought or for which it has applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(pp)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Investment
Company Act</I>. Neither the Company nor any subsidiary is and, after giving effect to the offering and sale of the Shares and the application
of the proceeds thereof, or the manner in which such proceeds are temporarily held pending expenditure, neither of them will be registered
or required to register as an &ldquo;investment company&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(qq)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>PFIC
and CFC</I>. The Company expects not to be a &ldquo;passive foreign investment company&rdquo; within the meaning of Section&nbsp;1297
of the Code for its current taxable year ending December&nbsp;31, 2023, or for the foreseeable future. The Company is not a &ldquo;controlled
foreign corporation&rdquo;, as defined in Section&nbsp;957 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(rr)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Absence
of Manipulation</I>. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly
or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or
manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares or to result in a violation of
Regulation M under the Exchange Act or Canadian Securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ss)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Foreign
Corrupt Practices Act</I>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent,
employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly
or indirectly, that would result in a violation by such persons of the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the
rules&nbsp;and regulations thereunder (the &ldquo;<U>FCPA</U>&rdquo;), the U.K. Bribery Act of 2010, the <I>Corruption of Foreign Public
Officials Act </I>(Canada), the <I>Criminal Code </I>(Canada), or any other applicable anti-bribery or anti-corruption laws implementing
the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offense
under any other applicable anti-bribery or anti-corruption laws (the &ldquo;<U>Anti-Corruption Laws</U>&rdquo;) including, without limitation,
(i)&nbsp;making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment,
promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving
of anything of value to any &ldquo;foreign official&rdquo; (as such term is defined in the FCPA) or any foreign political party or official
thereof or any candidate for foreign political office, in contravention of the Anti-Corruption Laws, and (ii)&nbsp;made, offered, agreed,
requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate,
payoff, influence payment, kickback or other unlawful or improper payment or benefit, and the Company has instituted, maintained and
enforced, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance with all applicable
anti-bribery and anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(tt)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Money
Laundering Laws</I>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, those
of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to
Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), those of Proceeds of Crime (Money Laundering) and Terrorist Financing
Act (Canada), and the applicable anti-money laundering statutes of all other jurisdictions to which the Company is subject, the rules&nbsp;and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental
Authority (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;); and no action, suit or proceeding by or before any Governmental
Authority involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge
of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(uu)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>OFAC</I>.
Neither the Company nor any of its subsidiaries nor any director or officer of the Company or its subsidiaries, nor, to the knowledge
of the Company, any agent, employee, affiliate or representative of the Company or any of its subsidiaries is an individual or entity
(&ldquo;<U>Person</U>&rdquo;), or is more than 50 percent owned in the aggregate by or acting on behalf of one or more Persons that are,
currently the subject or target, of any sanctions administered or enforced by the United States Government, including, without limitation,
the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets Control (&ldquo;<U>OFAC</U>&rdquo;), the Global Affairs Canada,
the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively,
 &ldquo;<U>Sanctions</U>&rdquo;), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory
that is the subject of Sanctions, (including, without limitation, Cuba,&nbsp;Iran, North Korea, Sudan, Syria, Russia, the Crimea region
of Ukraine, the so-called Donetsk People&rsquo;s Republic, the so-called Luhansk People&rsquo;s Republic, and any other &ldquo;Covered
Region&rdquo; of Ukraine identified pursuant to Executive Order 14065, each, a &ldquo;<U>Sanctioned Country</U>&rdquo;); and the Company
will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or
business with any person that, at the time of such funding or facilitation, is the subject or the target of Sanctions, (ii)&nbsp;to fund
or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation
by any person (including any person participating in the transaction, whether as agent, advisor, investor or otherwise) of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and its subsidiaries
have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any person
that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(vv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>No
Transfer Taxes or Other Fees</I>. There are no stamp or other issuance or transfer taxes or duties or other similar fees or charges payable
(either by direct assessment or withholding) in connection with the execution and delivery of this Agreement or the creation, issuance,
sale and delivery of the Shares or the resale of the Shares by the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ww)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Foreign
Private Issuer</I>. The Company is a &ldquo;foreign private issuer&rdquo; as defined in Rule&nbsp;405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(xx)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Reporting
Requirements</I>. The Company is, and will be at the Time of Sale, a reporting issuer in the Canadian Qualifying Jurisdictions and is
not on the list of defaulting reporting issuers maintained by any Canadian Qualifying Authorities that maintains such a list; the Company
is in compliance, in all material respects, with its continuous and timely disclosure obligations under Canadian Securities Laws and
under the rules&nbsp;and regulations of Nasdaq and the TSX and has filed all documents required to be filed by it with the Canadian Qualifying
Authorities under applicable Canadian Securities Laws; the Company has not filed any confidential material change reports with any of
the Canadian Qualifying Authorities that remain confidential at the date hereof; and the Company has filed a current annual information
form in the form prescribed by NI 51-102 in each of the Canadian Qualifying Jurisdictions prior to the date of this Agreement. The Company
is eligible to use the Canadian Shelf Procedures for the distribution of the Shares. The Company has complied with all Canadian Securities
Laws required to be complied with by the Company to qualify the distribution of the Shares through registrants registered in the applicable
categories under Canadian Securities Laws in each of the Canadian Qualifying Jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(yy)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Related
Party Transactions</I>. There are no business relationships or related-party transactions involving the Company, any subsidiary or any
other person required by applicable securities laws to be described in the Registration Statement, the Prospectuses and the Disclosure
Package that have not been described as required. To the Company&rsquo;s knowledge, none of the directors, officers or employees of the
Company, any of its subsidiaries or any associate or affiliate of any of the foregoing has any interest, direct or indirect, in any transaction
with the Company or any of its subsidiaries that materially affects, is material to or would reasonably be expected to materially affect
the Company or any of its subsidiaries. Except for wages, salaries and other compensation-related payments in the ordinary course, and
other than as disclosed in the Registration Statement, the Prospectuses or the Disclosure Package, neither the Company nor any of its
subsidiaries is indebted to: (i)&nbsp;any director, officer or shareholder of the Company; (ii)&nbsp;any individual related to any of
the foregoing by blood, marriage or adoption; or (iii)&nbsp;any corporation controlled, directly or indirectly, by any one or more of
those persons referred to in this Section&nbsp;2(yy). None of those persons referred to in this Section&nbsp;2(yy) is indebted to the
Company or any of its subsidiaries. Neither the Company nor any of its subsidiaries is currently a party to any material contract, agreement
or understanding with any officer, director, employee, shareholder or any other person not dealing at arm&rsquo;s length with the Company
or its subsidiaries other than employment agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(zz)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Immunity
from Jurisdiction</I>. Neither the Company nor any of its subsidiaries nor any of its or their properties or assets has any immunity
from the jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment
in aid of execution or otherwise) under the laws of Canada and the laws of the Province of Ontario. The irrevocable and unconditional
waiver and agreement of the Company contained in this Agreement not to plead or claim any such immunity in any legal action, suit or
proceeding based on this Agreement is valid and binding under the laws of Canada and the laws of the Province of Ontario. The choice
of the law of the State of New York as the governing law of this Agreement is a valid choice of law under the laws of Canada, and the
Company is not aware of any basis for avoiding the choice on the grounds of Ontario public policy, as that term is understood under the
laws of the Province of Ontario and the laws of Canada applicable therein. The Company has the power to submit, and has legally, validly,
effectively and irrevocably submitted, to the personal jurisdiction of each New York State and United States Federal court sitting in
The City of New York and has validly and irrevocably waived any objection to the laying of venue of any suit, action or proceeding brought
in any such court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By the execution and delivery
of this Agreement, the Company (i)&nbsp;acknowledges that it has, by separate written instrument, irrevocably designated and appointed
Profound Medical (U.S.) Inc. (together with any successor, the &ldquo;<U>Agent for Service</U>&rdquo;), as its authorized agent upon
which process may be served in any suit or proceeding arising out of or relating to this Agreement or the Securities, that may be instituted
in any federal or state court in the City and County of New York, Borough of Manhattan, or brought under federal or state securities
laws, and acknowledges that the Agent for Service has accepted such designation, (ii)&nbsp;submits to the non-exclusive jurisdiction
of any such court in any such suit or proceeding, and (iii)&nbsp;agrees that service of process upon the Agent for Service (or any successor)
and written notice of said service to the Company shall be deemed in every respect effective service of process upon the Company in any
such suit or proceeding. The Company further agrees to take any and all action, including the execution and filing of any and all such
documents and instruments, as may be necessary to continue such designation and appointment of the Agent for Service in full force and
effect so long as required by the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that the Company
has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process (whether through service of notice,
attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself or its property, it hereby
irrevocably waives, and agrees to cause each of its subsidiaries to waive, such immunity in respect of its obligations under the above-referenced
documents, to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(aaa)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Lending
and Other Relationships</I>. The Company (i)&nbsp;does not have any material lending or other relationship with any banking or lending
affiliate of any Agent and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Shares to repay any outstanding
debt owed to any affiliate of any Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(bbb)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Statistical
and Market-Related Data</I>. Any statistical and market-related data included or incorporated by reference in the Registration Statement,
the Prospectuses or the Disclosure Package are based on or derived from sources that the Company believes, after reasonable inquiry,
to be reliable and accurate in all material respects and, to the extent required, the Company has obtained the written consent to the
use of such data from such sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ccc)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Rating</I>.
The Company has no debt securities or preferred shares that are rated by any &ldquo;nationally recognized statistical rating organization&rdquo;
(as that term is defined in Section&nbsp;3(a)(62) of the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ddd)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Material
Transactions</I>. Except to the extent disclosed in the Registration Statement, the Prospectuses and the Disclosure Package or for discussions
or negotiations in the ordinary course of business, the Company is not currently party to any agreement in respect of: (i)&nbsp;the purchase
of any material assets and properties or any interest therein or the sale, transfer or other disposition of any material assets and properties
or any interest therein currently owned, directly or indirectly, by the Company whether by asset sale, transfer of shares or otherwise;
or (ii)&nbsp;the change of control of the Company (whether by sale or transfer of shares or sale of all or substantially all of the assets
and properties of the Company or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(eee)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Contracts</I>.
All material Applicable Agreements are in full force and effect and are valid and enforceable by and against the Company or its applicable
subsidiary, as the case may be, in accordance with their terms, except as enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium and other laws relating to or affecting the rights of creditors generally, and except as limited by the application
of equitable principals when equitable remedies are sought, and by the fact that the ability to sever unenforceable terms may be limited
by applicable law. Neither the Company nor any of its subsidiaries has sent or received any communication regarding termination of, or
intent not to renew, any of the material Applicable Agreements referred to or described in Registration Statement, the Prospectuses or
the Disclosure Package, and no such termination or non-renewal has been threatened by the Company or any of its subsidiaries or, to the
Company&rsquo;s knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal has not been
rescinded as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(fff)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Corporate
Records and Due Diligence</I>. Copies of the minute books and records of the Company and its subsidiaries made available to counsel for
the Agents in connection with the due diligence investigation of the Company and its subsidiaries for the period from the date of incorporation
to the date hereof are all of the minute books of the Company and its subsidiaries and contain copies of all material proceedings (or
certified copies thereof or drafts thereof pending approval) of the shareholders, the directors and all committees of directors of the
Company and its subsidiaries to the date hereof to the extent that minutes exist and there have been no other meetings, resolutions or
proceedings of the shareholders, directors or any committees of the directors of the Company or its subsidiaries to the date hereof not
reflected in such minute books. The Company has not withheld from the Agents any material facts relating to the Company, any of its subsidiaries
or the offering of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ggg)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Fees</I>.
Other than the Agents, there is no person acting or purporting to act at the request or on behalf of the Company that is entitled to
any brokerage or finder&rsquo;s fee or other compensation in connection with the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(hhh)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Eligible
Investment</I>. The Shares will at any Time of Sale and Settlement Date qualify as eligible investments as described in the Registration
Statement, the Prospectuses and the Disclosure Package under the heading &ldquo;Eligibility for Investment&rdquo; and the Company will
not take or permit any action within its control which would cause the Shares to cease to be qualified, during the period of distribution
of the Shares, as eligible investments to the extent so described in the Registration Statement, the Prospectuses and the Disclosure
Package.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Transfer
Agents</I>. TSX Trust Company, at its principal offices in Toronto, Ontario, has been duly appointed as the registrar and transfer agent
for the Common Shares in Canada and Computershare Trust Company, N.A., at its principal offices in Canton, Massachusetts, has been duly
appointed as the registrar and transfer agent for the Common Shares in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(jjj)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Acquisitions</I>.
The acquisitions of the respective businesses and/or companies disclosed in the Registration Statement, the Prospectuses and the Disclosure
Package were effected in compliance with all applicable laws, and no payments will accrue, be owing or be payable by, the Company or
any of its subsidiaries to any person in connection with any such acquisition except for any such payments as would not be material to
the Company and its subsidiaries (taken as a whole). No acquisition has been made by the Company during its three most recently completed
fiscal years that would be a significant acquisition for the purposes of Canadian Securities Laws or that would require the financial
statement disclosure in respect of the acquired business for the purposes of Canadian Securities Laws, and no proposed acquisition by
the Company has progressed to a state where a reasonable person would believe that the likelihood of the Company completing the acquisition
is high and that: (i)&nbsp;if completed by the Company at the date of the Prospectuses, would be a significant acquisition for the purposes
of Canadian Securities Laws, or (ii)&nbsp;would require the financial statement disclosure in respect of the acquired business for the
purposes of Canadian Securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(kkk)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Cybersecurity</I>.
There has been no security breach or other compromise of or relating to any information technology and computer systems, networks, hardware,
software, data (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by
or on behalf of them), equipment or technology of the Company or its subsidiaries (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;)
and the Company and its subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably
be expected to result in, any security breach or other compromise to their IT Systems and Data. The Company and its subsidiaries are
presently in compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect. The Company and its subsidiaries have implemented backup
and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(lll)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Insolvency</I>.
No event of insolvency has occurred in relation to the Company or its subsidiaries, nor is there, nor will there be at any Time of Sale
and Settlement Date, any act which has occurred or, to the best of the Company&rsquo;s knowledge, is anticipated to occur which is likely
to result in an event of insolvency in relation to the Company or its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(mmm)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Withholding
Taxes</I>. No withholding tax imposed under the federal laws of Canada or the Canadian Qualifying Jurisdictions will be payable in respect
of any commission or fee to be paid by the Company pursuant to this Agreement to the Agents that are &ldquo;non-residents&rdquo; within
the meaning of the <I>Income Tax Act</I> (Canada), provided any such commission or fee is payable in respect of services rendered by
such Agents, wholly outside of Canada and are performed in the ordinary course of business carried on by the Agents that includes the
performance of such services for a fee and such Agents deal at arm&rsquo;s length with the Company within the meaning of the <I>Income
Tax Act</I> (Canada) and any such amount is reasonable in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(nnn)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Officer&rsquo;s
Certificates</I>. Any certificate signed by any officer of the Company delivered to the Agents or to counsel for the Agents shall be
deemed a representation and warranty by the Company (and not individually by such officer) to each Agent as to the matters covered thereby
subject to the qualifications and limitations set out in such certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Agreements
of the Company</U>. The Company covenants and agrees with the Agents as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Prospectus
and Registration Statement Amendments</I>. After the date of this Agreement and until the completion of the sales contemplated hereunder,
(i)&nbsp;the Company will notify the Agents promptly of the time when any subsequent amendment to the Canadian Base Prospectus or the
Registration Statement has been filed with any Canadian Qualifying Authority or the Commission and has become effective or where a receipt
has been issued therefor, as applicable, or any subsequent supplement to the U.S. Prospectus or the Canadian Prospectus has been filed
(other than the filing of any documents incorporated by reference into the U.S. Prospectus or the Canadian Prospectus) (each, an &ldquo;<U>Amendment
Date</U>&rdquo;) and of any request by the Commission or any Canadian Qualifying Authority for any amendment or supplement to the Registration
Statement or the Prospectuses or for additional information; (ii)&nbsp;the Company will file promptly all other material required to
be filed by it with the Commission pursuant to Rule&nbsp;433(d)&nbsp;and with the Canadian Qualifying Authorities; (iii)&nbsp;the Company
will submit to the Agents a copy of any amendment or supplement to the Registration Statement or the Prospectuses (other than a copy
of any documents incorporated by reference into the Registration Statement or the Prospectuses) within a reasonable period of time before
the filing thereof and will afford the Agents and the Agents&rsquo; counsel a reasonable opportunity to comment on any such proposed
filing prior to such proposed filing; and (iv)&nbsp;the Company will furnish to the Agents at the time of filing thereof a copy of any
document that upon filing is deemed to be incorporated by reference in the Registration Statement or the Prospectuses (provided that
the Company shall not be required to deliver documents or information incorporated by reference into the Registration Statement or the
Prospectuses if such documents are accessible from SEDAR+ or EDGAR) and the Company will cause (x)&nbsp;each amendment or supplement
to the U.S. Prospectus to be filed with the Commission as required pursuant to General Instruction II.L of Form&nbsp;F-10 of the Rules&nbsp;and
Regulations or, in the case of any document to be incorporated therein by reference, to be filed with the Commission as required pursuant
to the Exchange Act, within the time period prescribed and (y)&nbsp;each amendment or supplement to the Canadian Prospectus to be filed
with the Canadian Qualifying Authorities as required pursuant to NI 44-101 and NI 44-102 (the &ldquo;<U>Canadian Shelf Procedures</U>&rdquo;)
or, in the case of any document to be incorporated therein by reference, to be filed with the Canadian Qualifying Authorities as required
pursuant to Canadian Securities Laws, within the time period prescribed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Notice
of Stop Orders</I>. The Company will advise the Agents, promptly after it receives notice thereof, of the issuance by the Commission
or the Canadian Qualifying Authorities of any stop order or of any order preventing or suspending the use of the Prospectuses or other
prospectus in respect of the Shares, of any notice of objection of the Commission to the use of the form of the Registration Statement
or any post-effective amendment thereto, of the suspension of the qualification of the Shares for offering or sale in the United States
or the Canadian Qualifying Jurisdictions, of the initiation or threatening of any proceeding for any such purpose, or of any request
by the Commission or the Canadian Qualifying Authorities for the amending or supplementing of the Registration Statement or the Prospectuses
or for additional information relating to the Shares. If there is an Agency Transaction Notice that has been issued by the Company that
has not been suspended or terminated in accordance with the notice requirements set forth in Section&nbsp;1(a)(iv)&nbsp;or Section&nbsp;7,
as applicable, the Company will use its commercially reasonable efforts to prevent the issuance of any stop order or any order preventing
or suspending the use of the Prospectuses or other prospectus in respect of the Shares, a notice of objection of the Commission to the
form of the Registration Statement or any post-effective amendment thereto or the suspension of any qualification for offering or sale
in the United States or the Canadian Qualifying Jurisdictions, and, in the event of the issuance of any such stop order or any such order
preventing or suspending the use of any prospectus relating to the Shares or suspending any such qualification, the Company will use
its commercially reasonable efforts to obtain the lifting or withdrawal of such order as soon as possible. If there is no such outstanding
Agency Transaction Notice, then, if, in the Company&rsquo;s determination and at the Company&rsquo;s sole discretion, it is necessary
to prevent the issuance of any stop order or have a stop order lifted, the Company will use its commercially reasonable efforts to prevent
the issuance of any stop order or any order preventing or suspending the use of the Prospectuses or other prospectus in respect of the
Shares, a notice of objection of the Commission to the form of the Registration Statement or any post-effective amendment thereto or
the suspension of any qualification for offering or sale in the United States or the Canadian Qualifying Jurisdictions, and, in the event
of the issuance of any such stop order or any such order preventing or suspending the use of any prospectus relating to the Shares or
suspending any such qualification, the Company will use its commercially reasonable efforts to obtain the lifting or withdrawal of such
order as soon as possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Delivery
of Prospectus; Subsequent Changes</I>. Within the time during which the Prospectuses are required to be delivered by the Agents under
the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;153, Rule&nbsp;172 or Rule&nbsp;173(a)&nbsp;under
the Securities Act) or Canadian Securities Laws, the Company will comply in all material respects with all requirements imposed upon
it by the Securities Act, by the Rules&nbsp;and Regulations, as appropriate and as from time to time in force, and will file or furnish
on or before their respective due dates all reports required to be filed or furnished by it with the Commission pursuant to Sections
13(a), 13(c), or 15(d)&nbsp;of the Exchange Act, if applicable, or any other provision of or under the Exchange Act or with the Canadian
Qualifying Authorities pursuant to Canadian Securities Laws, as appropriate. If during such period any event occurs as a result of which
the Prospectuses as then amended or supplemented would include an untrue statement of material fact or omit to state a material fact
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or if during
such period it is necessary to amend or supplement the Registration Statement or the Prospectuses to comply with the Securities Act or
Canadian Securities Laws, the Company will immediately notify the Agents to suspend the offering of Shares during such period and, if,
in the Company&rsquo;s determination and at the Company&rsquo;s sole discretion, it is necessary to file an amendment or supplement to
the Registration Statement or the Prospectuses to comply with the Securities Act or Canadian Securities Laws, the Company will promptly
prepare and file with the Canadian Qualifying Authorities and the Commission such amendment or supplement as may be necessary to correct
such statement or omission or to make the Registration Statement or the Prospectuses comply with such requirements, and the Company will
furnish to the Agents such number of copies of such amendment or supplement as the Agents may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Delivery
of Registration Statement and Prospectuses</I>. The Company will furnish to the Agents and their counsel (at the expense of the Company)
copies of the Registration Statement, the Prospectuses (including all documents incorporated by reference therein) and all amendments
and supplements to the Registration Statement or the Prospectuses that are filed with the Commission or Canadian Qualifying Authorities
during the period in which a prospectus relating to the Shares is required to be delivered under the Securities Act (including all documents
filed with the Commission during such period that are deemed to be incorporated by reference therein) or by the Canadian Qualifying Authorities
(including all documents filed with the Canadian Qualifying Authorities during such period that are deemed to be incorporated by reference
therein), in each case as soon as reasonably practicable and in such quantities as the Agents may from time to time reasonably request
provided, however, the Company shall not be required to furnish any documents to the Agents that are available on SEDAR+ or EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Company
Information</I>. The Company will furnish to the Agents such information in its possession as is reasonably requested by the Agents as
necessary or appropriate to fulfil their obligations as agents pursuant to this Agreement, the Securities Act and Canadian Securities
Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Compliance
with Blue Sky Laws</I>. The Company shall cooperate with the Agents and their counsel therefor in connection with the registration or
qualification (or the obtaining of exemptions therefrom) of the Shares for the offering and sale under the securities or blue sky laws
of such jurisdictions as the Agents may request, including, without limitation, the provinces and territories of Canada and other jurisdictions
outside of the United States, and to continue such registration or qualification in effect so long as necessary under such laws for the
distribution of the Shares; provided, however, that in no event shall the Company be obligated to qualify to do business in any jurisdiction
where it is not now so qualified or to take any action which would subject it to general service of process in any jurisdiction where
it is not now so subject (except service of process with respect to the offering and sale of the Shares). The Company will advise the
Agents promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering,
sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance
of any order suspending such qualification, registration or exemption, the Company shall use its reasonable efforts to obtain the withdrawal
thereof as soon as reasonably practicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Material
Non-public Information</I>. The Company covenants that it will not issue an Agency Transaction Notice to the Agents in accordance with
Section&nbsp;1 hereof if the Company is in possession of material non-public information regarding the Company and any of its subsidiaries,
taken as a whole, or the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Reimbursement
of Certain Expenses</I>. Whether or not any of the transactions contemplated by this Agreement are consummated or this Agreement is terminated,
the Company shall pay, or reimburse if paid by the Agents all costs and expenses incident to the performance of the obligations of the
Company under this Agreement, including, without limitation, costs and expenses of or relating to (i)&nbsp;the preparation, printing
and filing of the Registration Statement and exhibits to it, each preliminary prospectus, each Permitted Free Writing Prospectus, the
Prospectuses and any amendment or supplement to the Registration Statement or the Prospectuses (including the filing fees payable to
the Commission relating to the Shares within the time required by Rule&nbsp;456 of the Rules&nbsp;and Regulations), (ii)&nbsp;the preparation,
issuance and delivery of the Shares, including any transfer agent fees payable in connection therewith and the preparation and delivery
of certificates representing the Shares, if applicable, (iii)&nbsp;the printing of this Agreement, (iv)&nbsp;furnishing (including costs
of shipping, mailing and courier) such copies of the Registration Statement, the Prospectuses, any preliminary prospectus and any Permitted
Free Writing Prospectus, and all amendments and supplements thereto, as may be requested for use in connection with the offering and
sale of the Shares by the Agents, (v)&nbsp;the listing of the Shares on the Nasdaq and the TSX, (vi)&nbsp;any filings required to be
made by the Agents with FINRA and the filing fees incident to FINRA review, if any, the Commission and the Canadian Qualifying Authorities,
and the reasonable and documented fees, disbursements and other charges of counsel for the Agents in connection therewith, (vii)&nbsp;the
registration or qualification of the Shares for offer and sale under the Securities Act and the securities or blue sky laws of such jurisdictions
designated pursuant to Section&nbsp;3(f), including the reasonable and documented fees, disbursements and other charges of counsel to
the Agents in connection therewith, and, if requested by the Agents, the preparation and printing of preliminary, supplemental and final
blue sky or legal investment memoranda, (viii)&nbsp;counsel to the Company, (ix)&nbsp;The Depository Trust Company and any other depositary,
transfer agent or registrar for the Shares, (x)&nbsp;the accountants of the Company, (xi)&nbsp;the marketing of the offering of the Shares
by the Company, including, without limitation, all costs and expenses of commercial airline tickets, hotels, meals and other travel expenses
of officers, employees, agents and other representatives of the Company, (xii)&nbsp;the reasonable out-of-pocket fees, disbursements
and other charges of the Agents incurred on or prior to the date hereof in connection with this Agreement, the Registration Statement
and the Prospectuses, including, without limitation, the documented fees and disbursements of counsel, provided that (1)&nbsp;such
fees, disbursements and other charges of the Agents shall be paid upon receiving an invoice or invoices therefore from the Agents and
(2)&nbsp;such fees of counsel shall not exceed US$125,000 (exclusive of
taxes and disbursements) in the aggregate, (xiii)&nbsp;the reasonable out-of-pocket fees, disbursements and other charges of the Agents
incurred after the date hereof in connection with this Agreement, the Registration Statement and the Prospectuses, including, without
limitation, documented fees and disbursements of counsel, provided that such fees, disbursements and other charges
of the Agents shall be paid upon receiving an invoice or invoices therefore from the Agents and such fees of counsel shall not exceed
US$25,000 (exclusive of taxes and disbursements) in the aggregate per Representation Date (as defined herein) and (xiv)&nbsp;all fees,
costs and expenses for consultants used by the Company in connection with the offering of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Use
of Proceeds</I>. The Company shall apply the net proceeds from the offering and sale of the Shares to be sold by the Company in the manner
set forth in the Prospectuses under &ldquo;Use of Proceeds&rdquo; and the Company does not intend to use any of the proceeds from the
sale of the Shares to repay any outstanding debt owed to the Agents or any affiliate of the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Change
of Circumstances</I>. During the term of this Agreement, the Company will, at any time during a fiscal quarter in which the Company intends
to deliver an Agency Transaction Notice to the Agents to sell Shares, advise the Agents promptly after it has received notice or obtained
knowledge thereof, of any information or fact that would alter or affect in any material respect any opinion, certificate, letter or
other document provided to the Agents pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Due
Diligence Cooperation</I>. The Company shall cooperate with any reasonable due diligence review requested by the Agents or their counsel
from time to time in connection with the transactions contemplated hereby or any Agency Transaction Notice, including, without limitation,
(i)&nbsp;prior to the open of trading on each intended purchase date and any Time of Sale or Settlement Date, making available appropriate
corporate officers of the Company and, upon reasonable request, representatives of the accountants and auditors for the Company, an update
on diligence matters with representatives of the Agents and their counsel and (ii)&nbsp;at each Representation Date or otherwise as the
Agents may reasonably request, providing information and making available documents and appropriate corporate officers of the Company,
representatives of the accountants and auditors for the Company for one or more due diligence sessions with representatives of the Agents
and their counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Clear
Market</I>. The Company shall not offer to sell, pledge, hypothecate, contract or agree to sell, purchase any option to sell, grant any
option for the purchase of, lend, or otherwise dispose of, directly or indirectly, any Common Shares or any securities convertible into
or exercisable or exchangeable for Common Shares or warrants or other rights to acquire shares of Common Shares or any other securities
of the Company that are substantially similar to the Common Shares or permit the registration under the Securities Act of any Common
Shares, in each case without giving the Agents by written notice or by draft news release sent to the Agents at least one business day
prior to the issuance date specifying the nature and date of such proposed transaction. Notwithstanding the foregoing, the Company may,
without giving any such prior notice, (i)&nbsp;register the offering and sale of the Shares through the Agents pursuant to this Agreement,
(ii)&nbsp;issue Common Shares upon the exercise of any option or warrant, the vesting of any restricted stock unit, or the conversion
of a security outstanding on the date hereof and referred to in the Prospectuses, (iii)&nbsp;issue Common Shares, options or other securities
convertible into or exchangeable for Common Shares pursuant to existing equity incentive plans of the Company, (iv)&nbsp;issue Common
Shares pursuant to any non-employee director stock plan, dividend reinvestment plan, stock purchase plan or other similar incentive plan
of the Company, or (v)&nbsp;file any registration statement on Form&nbsp;S-8 or similar form with the Commission. If notice of a proposed
transaction is provided by the Company pursuant to this Section&nbsp;3(l), the Agents may suspend activity of the transactions contemplated
by this Agreement for such period of time as may be requested by the Company or as may be deemed appropriate by the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Affirmation
of Representations, Warranties, Covenants and Other Agreements</I>. Upon commencement of the offering of the Shares under this Agreement
(and upon the recommencement of the offering of the Shares under this Agreement following any suspension of sales under Section&nbsp;1(a)(iv)),
and at each Time of Sale, each Settlement Date and each Amendment Date, the Company shall be deemed to have affirmed each representation
and warranty contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Required
Filings Relating to Sale of Shares</I>. To the extent required by applicable Canadian Securities Laws and the Exchange Act, in each annual
and interim financial statement and related management&rsquo;s discussion and analysis or annual information form filed by the Company
in respect of any quarter or year, as applicable, in which sales of Shares were made by the Agents under this Agreement, the Company
shall set forth with regard to the most recent applicable quarter or year, as applicable, the number of Shares and the average selling
price of the Shares sold through the Agents under this Agreement, the gross and net proceeds received by the Company from such sales
of Shares and the compensation paid by the Company to the Agents with respect to sales of Shares pursuant to this Agreement. For so long
as the Shares are listed on the TSX, the Company will provide the TSX with all information it requires with respect to the offering of
the Shares within the timelines prescribed by the TSX and for so long as the Shares are listed on the Nasdaq, the Company will provide
the Nasdaq with all information it requires with respect to the offering of the Shares within the timelines prescribed by the Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Representation
Dates; Certificates</I>. During the term of this Agreement, each time the Company (i)&nbsp;files the Prospectuses relating to the Shares
or amends or supplements the Registration Statement or the Prospectuses relating to the Shares by means of a post-effective amendment
or supplement but not by means of incorporation of document(s)&nbsp;by reference to the Registration Statement or the Prospectuses relating
to the Shares; (ii)&nbsp;files or amends an annual information form or an annual report on Form&nbsp;20-F, Form&nbsp;40-F or Form&nbsp;10-K;
(iii)&nbsp;files or amends interim financial statements on Form&nbsp;6-K; (iv)&nbsp;files or amends annual or interim financial statements
pursuant to Canadian Securities Laws; or (v)&nbsp;at any other time reasonably requested by the Agents (each date of filing of one or
more of the documents referred to in clauses (i)&nbsp;through (iv)&nbsp;and any time of request pursuant to (v)&nbsp;above shall be a
 &ldquo;<U>Representation Date</U>&rdquo;), the Company shall furnish the Agents with certificates, in the forms included in Section&nbsp;4(d),
upon execution of this Agreement and within three Trading Days after each Representation Date. The requirement to provide certificates
under this Section&nbsp;3(o)&nbsp;shall be waived for any Representation Date occurring at a time at which no Agency Transaction Notice
is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Transaction Notice hereunder (which
for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date. Notwithstanding the
foregoing, if the Company subsequently decides to sell Shares following a Representation Date when the Company relied on such waiver
and did not provide the Agents with a certificate under this Section&nbsp;3(o)&nbsp;then before the Company delivers the Agency Transaction
Notice or the Agents sell any Shares, the Company shall provide the Agents with such certificate, in the corresponding form, as described
in Section&nbsp;4(d), dated the date of the Agency Transaction Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Legal
Opinions/Negative Assurance Letters</I>. Upon the execution of this Agreement and within three Trading Days after any Representation
Date, the Company shall cause to be furnished to the Agents, dated the date the opinions are so furnished and addressed to the Agents,
in form and substance reasonably satisfactory to the Agents, (i)&nbsp;the written opinion of Mintz LLP, Canadian counsel for the Company,
as described in Section&nbsp;4(e), and other local Canadian counsel or, in lieu of such opinions, counsel last furnishing such opinions
to the Agents may furnish the Agents with a letter to the effect that the Agents may rely on such last opinions to the same extent as
though they were dated the date of such letter authorizing reliance (except that statements in such last opinions shall be deemed to
relate to the Prospectus as amended and supplemented to the time of delivery of such letter authorizing reliance), as required; (ii)&nbsp;the
written opinion and a negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., U.S. counsel for the Company,
as described in Section&nbsp;4(e), or, in lieu of such opinions, counsel last furnishing such opinion to the Agents may furnish the Agents
with a letter to the effect that the Agents may rely on such last opinion to the same extent as though it was dated the date of such
letter authorizing reliance (except that statements in such last opinion shall be deemed to relate to the Registration Statement and
the Prospectuses as amended and supplemented to the time of delivery of such letter authorizing reliance); (iii)&nbsp;the written opinion
of Taylor Wessing LLP, German counsel for the Company, as described in Section&nbsp;4(e); (iv)&nbsp;the written opinion of Hannes
Snellman Attorneys Ltd., Finnish counsel for the Company, as described in Section&nbsp;4(e); and (v) the written opinion of Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C., regulatory counsel for the Company, as described in Section&nbsp;4(e). The requirement to furnish
the documents set out in this Section&nbsp;3(p)&nbsp;shall be waived for any Representation Date occurring at a time at which no Agency
Transaction Notice is pending or in effect, which waiver shall continue until the earlier to occur of the date the Company delivers an
Agency Transaction Notice hereunder (which for such calendar quarter shall be considered a Representation Date), and the next occurring
Representation Date; <I>provided, however</I> that such waiver shall not apply for any Representation Date on which the Company files
its annual report on Form 40-F, Form 20-F or Form 10-K. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares
following a Representation Date when the Company relied on such waiver, then before the Company delivers the Agency Transaction Notice,
or the Agents sell any Shares, the Company shall provide the Agents with each of the documents set out in this Section&nbsp;3(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Comfort
Letter</I>. Upon the filing of the Prospectus Supplements and within three Trading Days after each Representation Date, the Company shall
cause its auditors to furnish the Agents a letter (the &ldquo;<U>Comfort Letter</U>&rdquo;) dated the date the Comfort Letter is delivered,
in form and substance satisfactory to the Agents, acting reasonably, addressed to the Agents, relating to the verification of certain
of the financial information and statistical and accounting data relating to the Company and any subsidiaries contained in the Registration
Statement and the Prospectuses or incorporated by reference therein, which comfort letter shall be based on a review having a cut-off
date not more than two business days prior to the date of such letter, (i)&nbsp;stating that such auditors are independent public accountants
within the meaning of Canadian Securities Laws, the Securities Act and the rules&nbsp;and regulations thereunder, and that in their opinion
the audited financial statements of the Company incorporated by reference in the Registration Statement and the Prospectuses comply as
to form in all material respects with the published accounting requirements of Canadian Securities Laws, the Securities Act and the related
rules&nbsp;and regulations thereunder and with the applicable accounting requirements of Canadian Securities Laws, the Securities Act
and the Exchange Act and the related published rules&nbsp;and regulations adopted by the Canadian Qualifying Authorities and the Commission
(the first such letter, the &ldquo;<U>Initial Comfort Letter</U>&rdquo;) and (ii)&nbsp;updating the Initial Comfort Letter with any information
which would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the
Registration Statement and the Prospectuses, as amended and supplemented to the date of such letter. The requirement to furnish the documents
set out in this Section&nbsp;3(q)&nbsp;shall be waived for any Representation Date occurring at a time at which no Agency Transaction
Notice is pending or effective, which waiver shall continue until the earlier to occur of the date the Company delivers an Agency Transaction
Notice hereunder (which for such calendar quarter shall be considered a Representation Date), and the next occurring Representation Date.
Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Representation Date when the Company relied
on such waiver, then before the Company delivers the Agency Transaction Notice or the Agents sell any Shares, the Company shall provide
the Agents with each of the documents set out in this Section&nbsp;3(q).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>[Intentionally
Omitted]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Market
Activities</I>. The Company will not, directly or indirectly, (i)&nbsp;take any action designed to or that would constitute or that might
reasonably be expected to cause or result in, under Canadian Securities Laws or the Exchange Act or otherwise, stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of the Shares or (ii)&nbsp;sell, bid for, or purchase the
Shares, or pay anyone any compensation for soliciting purchases of the Shares other than the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Investment
Company Act</I>. The Company will conduct its affairs in such a manner so as to reasonably ensure that prior to the termination of this
Agreement, it will not be or become required to register as an &ldquo;investment company&rdquo; under the Investment Company Act and
the rules&nbsp;and regulations of the Commission promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Board
Authorization</I>. Prior to delivering notice of the proposed terms of an Agency Transaction pursuant to Section&nbsp;1 (or at such time
as otherwise agreed between the Company and the Agents), the Company shall have (i)&nbsp;obtained from its board of directors or a duly
authorized committee thereof all necessary corporate authority for the sale of the Shares pursuant to the relevant Agency Transaction,
and (ii)&nbsp;provided to the Agents a copy of the relevant board or committee resolutions or other authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Offer
to Refuse to Purchase</I>. If to the knowledge of the Company any condition set forth in Section&nbsp;4(a)&nbsp;of this Agreement shall
not have been satisfied on the applicable Settlement Date, the Company shall offer to any person who has agreed to purchase Shares from
the Company as the result of an offer to purchase solicited by the Agents the right to refuse to purchase and pay for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(w)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Consent
to the Agents&rsquo; Trading</I>. The Company consents to the extent permitted under the Securities Act, the Exchange Act, Canadian Securities
Laws, the rules&nbsp;of the Nasdaq, the rules&nbsp;of the TSX and under this Agreement, to the Agents trading in the Common Shares of
the Company: (i)&nbsp;for the account of their clients at the same time as sales of Shares occur pursuant to this Agreement; and (ii)&nbsp;for
the Agents&rsquo; own accounts, provided that in the case of clause (ii), no such purchase or sale shall take place by an Agent while
such Agent has received an Agency Transaction Notice that remains in effect, unless the Company has expressly authorized or consented
in writing to any such trades by such Agent, and provided further that in the case of clauses (i)&nbsp;and (ii), by providing such consent,
the Company will incur no liability on behalf of the Agents or their clients resulting from such trading activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Permitted
Free Writing Prospectuses</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company represents and agrees that it has not made and, unless it obtains the prior written consents of the Agents, shall not make, any
offer relating to the Shares that would constitute a &ldquo;free writing prospectus&rdquo; as defined in Rule&nbsp;405 of the Rules&nbsp;and
Regulations, which is required to be retained by the Company under Rule&nbsp;433 of the Rules&nbsp;and Regulations; provided that the
prior written consents of the Agents hereto shall be deemed to have been given in respect of each of the free writing prospectuses set
forth in <U>Schedule 3</U> hereto. Any such free writing prospectus consented to by the Agents is herein referred to as a &ldquo;<U>Permitted
Free Writing Prospectus</U>&rdquo;. The Company represents and agrees that (i)&nbsp;it has treated and shall treat, as the case may be,
each Permitted Free Writing Prospectus as a &ldquo;free writing prospectus&rdquo; as defined in Rule&nbsp;405 of the Rules&nbsp;and Regulations
and (ii)&nbsp;it has complied and shall comply, as the case may be, with the requirements of Rules&nbsp;164 and 433 of the Securities
Act applicable to any Permitted Free Writing Prospectus, including, without limitation, in respect of timely filing with the Commission,
legending and record keeping. The Company agrees not to take any action that would result in the Agents or the Company being required
to file pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing prospectus prepared by or on behalf of the Agents that
the Agents otherwise would not have been required to file thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company agrees that no Permitted Free Writing Prospectus, if any, will include any information that conflicts with the information contained
in the Registration Statement, including any document incorporated by reference therein that has not been superseded or modified, or
the Prospectuses. In addition, no Permitted Free Writing Prospectus, if any, together with the Prospectuses, will include an untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading; provided however, the foregoing shall not apply to any statements or omissions in any Permitted Free
Writing Prospectus made in reliance on information furnished in writing to the Company by the Agents expressly stating that such information
is intended for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company agrees that if at any time following issuance of a Permitted Free Writing Prospectus any event occurred or occurs as a result
of which such Permitted Free Writing Prospectus would conflict with the information in the Registration Statement, including any document
incorporated by reference therein that has not been superseded or modified, or the Prospectuses or would include an untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading, the Company will give prompt notice thereof to the Agents and, if requested by the Agents, will prepare
and furnish without charge to the Agents a Permitted Free Writing Prospectus or other document which will correct such conflict, statement
or omission; provided, however, the foregoing shall not apply to any statements or omissions in any Permitted Free Writing Prospectus
made in reliance on information furnished in writing to the Company by the Agents expressly stating that such information is intended
for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(y)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Distribution
of Offering Materials</I>. The Company has not distributed and will not distribute, during the term of this Agreement, any &ldquo;marketing
materials&rdquo; (as defined in National Instrument 41-101 - <I>General Prospectus Requirements</I>) in connection with the offering
and sale of the Shares other than the Registration Statement, the Prospectuses or any Permitted Free Writing Prospectus reviewed and
consented to by the Agents and included in an Agency Transaction Notice, provided that the Agents, severally and not jointly, covenant
with the Company not to take any action that would result in the Company being required to file with the Canadian Qualifying Authorities
any &ldquo;marketing materials&rdquo; that otherwise would not be required to be filed by the Company, but for the action of the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conditions
to the Agents&rsquo; Obligations</U>. The obligations of the Agents hereunder are subject to (i)&nbsp;the accuracy of the representations
and warranties of the Company on the date hereof, on each Representation Date and as of each Time of Sale and each Settlement Date, (ii)&nbsp;the
performance of the Company of its obligations hereunder and (iii)&nbsp;the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Canadian
Prospectus Supplement</I>. The Canadian Prospectus Supplement shall have been filed with the Canadian Qualifying Authorities under the
Canadian Shelf Procedures and in accordance with this Agreement and all requests for additional information on the part of the Canadian
Qualifying Authorities shall have been complied with to the reasonable satisfaction of the Agents and the Agents&rsquo; counsel and the
Translation Decision shall remain in full force and effect without amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>No
Material Adverse Changes</I>. Since the date of the most recent financial statements of the Company included or incorporated by reference
in the Registration Statement and the Prospectuses, there shall not have been a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>No
Material Notices</I>. None of the following events shall have occurred and be continuing: (i)&nbsp;receipt by the Company of any request
for additional information from the Commission, the Canadian Qualifying Authorities or any other federal or state or foreign or other
governmental, administrative or self-regulatory authority during the period of effectiveness of the Registration Statement and the Prospectuses,
the response to which would require any amendments or supplements to the Registration Statement or the Prospectuses; (ii)&nbsp;the issuance
by the Commission, the Canadian Qualifying Authorities or any other federal or state or foreign or other Governmental Authority of any
stop order suspending the effectiveness of the Registration Statement or the Prospectuses or the initiation of any proceedings for that
purpose; (iii)&nbsp;receipt by the Company of any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose;
(iv)&nbsp;the occurrence of any event that makes any statement made in the Registration Statement or the Prospectuses or any document
incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes
in the Registration Statement, the Prospectuses or any document incorporated or deemed to be incorporated therein by reference so that,
in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein not misleading, and in the case of each of the Prospectuses,
it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading; and (v)&nbsp;the Company&rsquo;s
reasonable determination that a post-effective amendment to the Registration Statement or Prospectuses would be appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Officers&rsquo;
Certificates</I>. The Company shall cause to be furnished to the Agents, and the Agents shall have received, upon execution of this Agreement
and within three Trading Days after each Representation Date, one or more accurate certificates, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Officer&rsquo;s
Certificate</I>. A certificate of an officer of the Company dated the date the certificate is delivered and signed by an officer of the
Company, in form and substance reasonably satisfactory to the Agents, to the effect set forth in clauses (b)&nbsp;and (c)&nbsp;above
and to the effect that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
signatory of such certificate has carefully examined the Registration Statement, the Prospectuses (including any documents filed under
the Exchange Act and Canadian Securities Laws and deemed to be incorporated by reference into the Prospectuses) and each Permitted Free
Writing Prospectus, if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">as
of such date and as of each Time of Sale subsequent to the immediately preceding Representation Date, if any, neither the
Registration Statement, the Prospectuses nor any Permitted Free Writing Prospectus contained any untrue statement of a material fact
or omitted to state any material fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
of the representations and warranties of the Company contained in this Agreement are true and correct on and, as of such date and
each Time of Sale subsequent to the immediately preceding Representation Date, if any, are true and correct in all material respects,
other than those that are qualified by materiality, which are true and correct, and with the same force and effect
as if expressly made on and as of such date, except for those representations and warranties that speak solely as of a specific date
and which were true and correct other than those that are qualified by materiality, which are true and
correct in all respects, as of such date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
of the covenants and agreements required herein to be performed by the Company on or prior to such date has been duly, timely and fully
performed and each condition herein required to be complied with by the Company on or prior to such date has been duly, timely and fully
complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Officer&rsquo;s
Certificate</I>. A certificate of an officer of the Company dated the date the certificate is delivered and signed by such officer ,
(i)&nbsp;certifying that attached thereto are true and complete copies of the resolutions duly adopted by the board of directors of the
Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including
the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of
such certificate, (ii)&nbsp;certifying and attesting to the office, incumbency, due authority and specimen signatures of each person
who executed this Agreement for or on behalf of the Company, (iii)&nbsp;certifying that attached thereto are true and complete copies
of the articles and by-laws of the Company, and (iv)&nbsp;containing any other certification that the Agents shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Chief
Financial Officer&rsquo;s Certificate</I>. A certificate of the Chief Financial Officer of the Company substantially in the form of <U>Exhibit&nbsp;B
</U>hereto, dated the date the certificate is delivered, certifying certain financial information set forth in the Registration Statement,
Prospectuses and Disclosure Package.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Legal
Opinions/Negative Assurance Letters</I>. The Agents shall have received the opinions of counsel and negative assurance letter to be delivered
pursuant to Section&nbsp;3(p)&nbsp;on or before the date on which such delivery of such opinions or negative assurance letter are required
pursuant to Section&nbsp;3(p). In addition, on such dates that the opinions required by Section&nbsp;3(p)&nbsp;are delivered, the Agents
shall have also received the opinion and negative assurance letter of Paul Hastings LLP, U.S. counsel to the Agents, with respect to
such matters as the Agents may reasonably require, it being understood that counsel for the Agents and counsel for the Company may rely
upon the opinions of local counsel as to all matters not governed by the laws of the respective jurisdictions in which they are qualified
to practice, and may rely, to the extent appropriate in the circumstances, as to matters of fact on certificates of the Company, auditors
and public officials, and that the opinions of counsel may be subject to usual qualifications as to equitable remedies, creditors&rsquo;
rights laws and public policy considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Comfort
Letter</I>. The Agents shall have received the Comfort Letter required to be delivered pursuant to Section&nbsp;3(q)&nbsp;on or before
the date on which such delivery of such letter is required pursuant to Section&nbsp;3(q).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Due
Diligence</I>. The Company shall have complied with all of its due diligence obligations required pursuant to Section&nbsp;3(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Compliance
with Blue Sky Laws</I>. The Shares shall be qualified for sale in such states and jurisdictions in the United States as the Agents may
reasonably request, as well as such jurisdictions outside the United States as the Agents may reasonably request, and each such qualification
shall be in effect and not subject to any stop order or other proceeding on the relevant Representation Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Stock
Exchange Listing</I>. The Shares shall have been duly authorized for listing on the Nasdaq and the TSX, subject only to notice of issuance
at or prior to the applicable Settlement Date. The Company will maintain the listing of the Shares on the Nasdaq and the TSX and the
Company will keep available, at all times, free of preemptive rights, Shares for the purpose of enabling the Company to satisfy its obligations
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Securities
Act Filings Made</I>. All filings with the Commission required by General Instruction II.L of Form&nbsp;F-10, the Securities Act and
required by the Canadian Qualifying Authorities to have been filed prior to the issuance of any Agency Transaction Notice hereunder shall
have been made within the applicable time period prescribed for such filing by General Instruction II.L of Form&nbsp;F-10, the Securities
Act and Canadian Securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>FINRA</I>.
If a filing with FINRA is required, FINRA shall not have objected to the fairness or reasonableness of the terms or arrangements under
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Additional
Certificates</I>. The Company shall have furnished to the Agents such certificate or certificates, in addition to those specifically
mentioned herein, as the Agents may have reasonably requested as to the accuracy and completeness at each Representation Date of any
statement in the Registration Statement or the Prospectuses or any documents filed under the Exchange Act and Canadian Securities Laws
and deemed to be incorporated by reference into the Prospectuses, as to the accuracy at such Representation Date of the representations
and warranties of the Company herein, as to the performance by the Company of its obligations hereunder, or as to the fulfillment of
the conditions concurrent and precedent to the obligations hereunder of the Agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Transfer
Agent</I>. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Press
Release</I>. Concurrently with the execution of this Agreement, the Company shall have issued and disseminated, and filed with the Canadian
Qualifying Authorities, a news release (i)&nbsp;announcing that the Company has entered into this Agreement, (ii)&nbsp;indicating that
the Prospectus Supplements have been or will be filed, (iii)&nbsp;specifying where and how a purchaser of Shares may obtain a copy of
this Agreement and the Prospectus Supplements and (iv)&nbsp;if applicable, that the completion of the distribution of Shares would constitute
a material fact or material change. Promptly after the execution of this Agreement, and in any event before any sales of Shares are made
hereunder, the Company shall file this Agreement with the Canadian Qualifying Authorities in accordance with applicable Canadian Securities
Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Indemnification
of the Agents</I>. The Company shall indemnify and hold harmless each of the Agents, the directors, officers, employees, counsel and
agents of each of the Agents and each person, if any, who controls any Agent within the meaning of Section&nbsp;15 of the Securities
Act or Section&nbsp;20 of the Exchange Act from and against any and all losses, claims, liabilities, expenses and damages (including,
without limitation, any and all investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in
settlement of, any action, suit or proceeding between any of the indemnified parties and any indemnifying
parties or between any indemnified party and any third party, or otherwise, or any claim asserted), to which they, or any of them, may
become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise,
insofar as such losses, claims, liabilities, expenses or damages arise out of or are based on (i)&nbsp;any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including all documents incorporated
therein by reference, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to
make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained
in any Permitted Free Writing Prospectus or the Prospectuses (or any amendment or supplement thereto) or the omission or alleged omission
therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading or (iii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any materials or
information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Shares,
including any roadshow or investor presentations made to investors by the Company (whether in person or electronically) or the omission
or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <I>provided</I>, <I>however</I>, that the Company shall not be liable to the extent that
such loss, claim, liability, expense or damage arises from the sale of the Shares pursuant to the Agreement and is based on an untrue statement or omission or alleged untrue statement or omission made in reliance on and in conformity with information
relating to the Agents furnished in writing to the Company by the Agents expressly for inclusion in the Registration Statement, the Prospectuses
or any Permitted Free Writing Prospectus, it being understood and agreed that the only such information consists of the Agent Information. This indemnity will be in addition to any liability that the Company might otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Indemnification
of the Company</I>. Each Agent shall, severally and not jointly, indemnify and hold harmless the Company, its agents, each person, if
any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, each
director of the Company and each officer of the Company who signs the Registration Statement to the same extent as the foregoing indemnity
from the Company to the Agents, but only insofar as losses, claims, liabilities, expenses or damages arise out of or are based on any
untrue statement or omission or alleged untrue statement or omission made in reliance on and in conformity with information relating
to an Agent furnished in writing to the Company by an Agent expressly for inclusion in the Registration Statement, any Permitted Free
Writing Prospectus or the Prospectuses. This indemnity will be in addition to any liability that the Agents might otherwise have. The
Company acknowledges that the Agent Information constitutes the only information furnished
in writing by or on behalf of the Agents for inclusion in the Registration Statement, any Permitted Free Writing Prospectus or the Prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Indemnification
Procedures</I>. Any party that proposes to assert the right to be indemnified under this Section&nbsp;5 shall, promptly after receipt
of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or
parties under this Section&nbsp;5, notify each such indemnifying party in writing of the commencement of such action, enclosing a copy
of all papers served, but the failure to so notify such indemnifying party shall not relieve the indemnifying party from any liability
that it may have to any indemnified party under the foregoing provisions of this Section&nbsp;5 unless, and only to the extent that,
such omission results in the forfeiture or material impairment of substantive rights or defenses by the indemnifying party. If any such
action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will
be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after
receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified,
to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying
party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party
for any legal or other expenses except as provided below and except for the reasonable costs of investigation subsequently incurred by
the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel in any such
action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (i)&nbsp;the
employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (ii)&nbsp;the indemnified party
has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that
are different from or in addition to those available to the indemnifying party, (iii)&nbsp;a conflict or potential conflict exists (based
on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying
party shall not have the right to direct the defense of such action on behalf of the indemnified party) or (iv)&nbsp;the indemnifying
party has not in fact employed counsel to assume the defense of such action within a reasonable time after receiving notice of the commencement
of the action, in each of which cases the reasonable fees, disbursements and other charges of counsel shall be at the expense of the
indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or
related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate
firm admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements
and other charges shall be reimbursed by the indemnifying party promptly as they are incurred. An indemnifying party shall not, in any event, be liable for
any settlement of any action or claim effected without its written consent. No indemnifying party shall, without the prior written consent
of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or
proceeding relating to the matters contemplated by this Section&nbsp;5 (whether or not any indemnified party is a party thereto), unless
such settlement, compromise or consent (x)&nbsp;includes an unconditional release of each indemnified party from all liability arising
or that may arise out of such claim, action or proceeding and (y)&nbsp;does not include a statement as to or an admission of fault, culpability
or a failure to act by or on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Contribution</I>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing
paragraphs of this Section&nbsp;5 is applicable in accordance with its terms but for any reason is held to be unavailable from the
Company or the Agents, the Company and the Agents shall contribute to the total losses, claims, liabilities, expenses and damages
(including, without limitation, any investigative, legal and other expenses reasonably incurred in connection with, and any amount
paid in settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the
Company from persons other than the Agents, such as persons who control the Company within the meaning of the Securities Act,
officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution)
to which the Company and the Agents may be subject in such proportion as shall be appropriate to reflect the relative benefits
received by the Company on the one hand and the Agents on the other hand. The relative benefits received by the Company on the one
hand and the Agents on the other hand shall be deemed to be in the same proportion as the total net proceeds from the offering
(before deducting expenses) received by the Company to the total compensation to actually received by the Agents pursuant to
Section&nbsp;1(a)(vii)&nbsp;(in the case of one or more Agency Transactions hereunder). If, but only if, the allocation provided by
the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is
appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the
Company, on the one hand, and the Agents, on the other hand, with respect to the statements or omissions which resulted in such
loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with
respect to such offering. Such relative fault shall be determined by reference to whether the untrue or alleged untrue statement of
a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the
Agents, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such
statement or omission. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense or
damage, or action in respect thereof, referred to above in this Section&nbsp;5(d)&nbsp;shall be deemed to include, for the purpose
of this Section&nbsp;5(d), any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this Section&nbsp;5(d), no Agent shall not be
required to contribute any amount in excess of the total compensation actually received by such Agent pursuant to
Section&nbsp;1(a)(vii)&nbsp;(in the case of one or more Agency Transactions hereunder), and no person found guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any
person who was not guilty of such fraudulent misrepresentation. For purposes of this Section&nbsp;5(d), any person who controls a
party to this Agreement within the meaning of the Securities Act will have the same rights to contribution as that party, and each
officer of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in
each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any
action against such party in respect of which a claim for contribution may be made under this Section&nbsp;5(d), will notify any
such party from whom contribution may be sought, but the failure to so notify will not relieve the party from whom contribution may
be sought from any other obligation it may have under this Section&nbsp;5(d)&nbsp;unless, and only to the extent that, such omission
results in any increase in the liability to contribute pursuant to this Section 5(d) that the party would not otherwise have had the
other contributing party given notice. No party will be liable for contribution with respect to any action or
claim settled without its written consent (which consent will not be unreasonably withheld).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Beneficiaries</I>.
The obligations of the Company under this Section&nbsp;5 shall be in addition to any liability which the Company may otherwise have and
shall extend, upon the same terms and conditions, to any affiliate of an Agent and each person, if any, who controls an Agent or any
such affiliate within the meaning of the Securities Act; and the obligations of the Agents under this Section&nbsp;5 shall be in addition
to any liability which it may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the
Company and to each person, if any, who controls the Company within the meaning of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company may terminate this Agreement in its sole discretion at any time upon giving prior written notice to the Agents. Any such termination
shall be without liability of any party to the other party, except that (i)&nbsp;with respect to any pending sale, the obligations of
the Company, including, without limitation, in respect of compensation of the Agents, shall remain in full force and effect notwithstanding
such termination; and (ii)&nbsp;the provisions of Sections 2&nbsp;(<I>Representations and Warranties of the Company</I>), 3 (<I>Agreements
of the Company</I>) (except that if no Shares have been previously sold hereunder, only Section&nbsp;3(h)&nbsp;(<I>Reimbursement of Certain
Expenses</I>)), 5 (<I>Indemnification</I>), 7(d)&nbsp;(<I>Survival of Representations and Warranties</I>), 7(f)&nbsp;(<I>Governing Law</I>)
and 7(m)&nbsp;(<I>Waiver of Jury Trial</I>) of this Agreement shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
Agent may terminate its obligations under this Agreement solely with respect to such Agent in its sole discretion at any time upon giving
prior written notice to the Company. Any such termination shall be without liability of any party to another party, except that (i)&nbsp;with
respect to any pending sale, the obligations of the Company, including, without limitation, in respect of compensation of the Agents,
shall remain in full force and effect notwithstanding such termination; and (ii)&nbsp;the provisions of Sections 2 (<I>Representations
and Warranties of the Company</I>), 3 (<I>Agreements of the Company</I>) (except that if no Shares have been previously sold hereunder,
only Section&nbsp;3(h)&nbsp;(<I>Reimbursement of Certain Expenses</I>)), 5&nbsp;(<I>Indemnification</I>), 7(d)&nbsp;(<I>Survival of Representations
and Warranties</I>), 7(f)&nbsp;(<I>Governing Law</I>) and 7(m)&nbsp;(<I>Waiver of Jury Trial</I>) of this Agreement shall remain in full
force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Agreement shall remain in full force and effect until the earliest to occur of (i)&nbsp;termination of this Agreement pursuant to Section&nbsp;6(a)&nbsp;or
6(b)&nbsp;above or otherwise by mutual written agreement of the parties, (ii)&nbsp;such date that the aggregate gross sales proceeds
of the Shares sold pursuant to this Agreement equals the Maximum Amount and (iii)&nbsp;April&nbsp;23, 2024, in each case except that
(x)&nbsp;with respect to any pending sale, the obligations of the Company, including, without limitation, in respect of compensation
of the Agents, shall remain in full force and effect notwithstanding such termination; and (y)&nbsp;the provisions of Sections 2 (<I>Representations
and Warranties of the Company</I>), 3 (<I>Agreements of the Company</I>) (except that if no Shares have been previously sold hereunder,
only Section&nbsp;3(h)&nbsp;(<I>Reimbursement of Certain Expenses</I>)), 5&nbsp;(<I>Indemnification</I>), 7(d)&nbsp;(<I>Survival of Representations
and Warranties</I>), 7(f)&nbsp;(<I>Governing Law</I>) and 7(m)&nbsp;(<I>Waiver of Jury Trial</I>) of this Agreement shall remain in full
force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
termination of this Agreement shall be effective on the date specified in the notice of termination; <I>provided</I> that such termination
shall not be effective until the close of business on the date of receipt of such notice by the Agents or the Company, as the case may
be. If such termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall settle in accordance with the
provisions of Section&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Notices</I>.
Notice given pursuant to any of the provisions of this Agreement shall be in writing and, unless otherwise specified, shall be mailed,
hand delivered or emailed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;if to the
Agents, at the offices of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Stifel Nicolaus Canada Inc.<BR>
161 Bay Street, Suite&nbsp;3800<BR>
Toronto, ON M5J 2S1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Brandon Roopnarinesingh<FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">E-mail:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">- and -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Stifel, Nicolaus&nbsp;&amp; Company,&nbsp;Incorporated<BR>
One South Street<BR>
15th Floor<BR>
Baltimore, Maryland 21202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Daniel Covatta<FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">E-mail:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">- with a copy to (which shall not constitute notice) &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Paul Hastings LLP<BR>
200 Park Avenue<BR>
New York, NY 10166</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Brandon
Bortner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">- and -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Osler, Hoskin&nbsp;&amp; Harcourt LLP<BR>
100 King Street West, 1 First Canadian Place<BR>
Suite&nbsp;6200, P.O.&nbsp;Box 50<BR>
Toronto ON&nbsp; M5X 1B8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Rob
Lando&nbsp;&amp; Amelia Miao</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">(ii)&nbsp;or if sent to the Company, at the office of the
Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Profound Medical Corp.<BR>
2400 Skymark Avenue, Unit #6<BR>
Mississauga, Ontario L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Arun
Menawat, Chief Executive Officer and Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">- with a copy to (which shall not constitute notice) -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Mintz LLP<BR>
200 Bay St, South Tower, Suite&nbsp;2800<BR>
Toronto, ON M5J 2J3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Cheryl
Reicin&nbsp;&amp; Eric Foster</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any such notice shall be deemed given and effective
(i)&nbsp;when sent, if emailed on or before 5:00 p.m.&nbsp;Eastern time on a Business Day or, if such day is not a Business Day, on the
next succeeding Business Day, (ii)&nbsp;upon receipt, if hand delivered, or (iii)&nbsp;five Business Days after being deposited in the
U.S. mail or Canada post, postage prepaid, if sent by mail. As used herein, &ldquo;Business Day&rdquo; means any day other than a Saturday
or a Sunday on which Schedule I Canadian chartered banks are open for business in Toronto, Ontario and Nasdaq and commercial banks in
the City of New York are open for business. Any notice under Section&nbsp;5 may be made by telecopy or telephone, but if so made shall
be subsequently confirmed in writing (which may include, in the case of the Agents, electronic mail to any Authorized Company Representative).
Any party to this Agreement may change its address for notice by notice to the other parties to this Agreement given in the manner provided
for by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company irrevocably (i)&nbsp;agrees that any legal suit, action or proceeding against the Company brought by an Agent or by any person
who controls an Agent arising out of or based upon this Agreement or the transactions contemplated thereby may be instituted in the courts
of the State of New York, (ii)&nbsp;waives, to the fullest extent it may effectively do so, any objection which it may now or hereafter
have to the laying of venue of any such proceeding and (iii)&nbsp;submits to the exclusive jurisdiction of such courts in any such suit,
action or proceeding. To the extent that the Company has or hereafter may acquire any immunity from jurisdiction of any court or from
any legal process (whether through service of notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise)
with respect to itself or its property, it hereby irrevocably waives such immunity in respect of its obligations under the above-referenced
documents, to the extent permitted by law. The provisions of this Section&nbsp;7(b)&nbsp;shall survive any termination of this Agreement,
in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>No
Third Party Beneficiaries</I>. The Company acknowledges and agrees that the Agents are acting solely in the capacity of arm&rsquo;s length
contractual counterparties to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining
the terms of the offering) and not as financial advisors or fiduciaries to, or agents of, the Company or any other person. Additionally,
the Agents are not advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any
jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent
investigation and appraisal of the transactions contemplated hereby, and the Agents shall have no responsibility or liability to the
Company with respect thereto. Any review by the Agents of the Company, the transactions contemplated hereby or other matters relating
to such transactions will be performed solely for the benefit of the Agents and shall not be on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Survival
of Representations and Warranties</I>. All representations, warranties and agreements of the Company contained herein or in certificates
or other instruments delivered pursuant hereto shall remain operative and in full force and effect regardless of any investigation made
by or on behalf of the Agents or any of their controlling persons and shall survive delivery of and payment for the Shares hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Disclaimer
of Fiduciary Relationship</I>. The Company acknowledges and agrees that (i)&nbsp;the purchase and sale of the Shares pursuant to this
Agreement, including the determination of the terms of the offering and any related discounts and commissions, is an arm&rsquo;s-length
commercial transaction between the Company, on the one hand, and the Agents, on the other hand, (ii)&nbsp;in connection with the offering
contemplated by this Agreement and the process leading to such transaction, the Agents owe no fiduciary duties to the Company or its
securityholders, creditors, employees or any other party, (iii)&nbsp;the Agents have not assumed nor will they assume any advisory or
fiduciary responsibility in favor of the Company with respect to the offering of the Shares contemplated by this Agreement or the process
leading thereto (irrespective of whether the Agents or their affiliates have advised or are currently advising the Company on other matters)
and the Agents have no obligation to the Company with respect to the offering of the Shares contemplated by this Agreement except the
obligations expressly set forth in this Agreement, (iv)&nbsp;the Agents and their affiliates may be engaged in a broad range of transactions
that involve interests that differ from those of the Company and (v)&nbsp;the Agents have not provided any legal, accounting, regulatory
or tax advice with respect to the offering contemplated by this Agreement and the Company has consulted its own legal, accounting, regulatory
and tax advisors to the extent it deemed appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Governing
Law</I>. THIS AGREEMENT, AND ANY DISPUTE, CLAIM OR CONTROVERSY ARISING UNDER OR RELATED TO THIS AGREEMENT, SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE. Each
party hereto hereby irrevocably submits for purposes of any action arising from this Agreement brought by any other party hereto to the
jurisdiction of the courts of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Judgment
Currency</I>. The Company agrees to indemnify each Agent, their directors, officers, affiliates and each person, if any, who controls
an Agent within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, against any loss incurred
by the Agents as a result of any judgment or order being given or made for any amount due hereunder and such judgment or order being
expressed and paid in a currency (the &ldquo;<U>Judgment Currency</U>&rdquo;) other than U.S. dollars and as a result of any variation
as between (i)&nbsp;the rate of exchange at which the U.S. dollar amount is converted into the Judgment Currency for the purpose of such
judgment or order, and (ii)&nbsp;the rate of exchange at which such indemnified person is able to purchase U.S. dollars with the amount
of the Judgment Currency actually received by the indemnified person. The foregoing indemnity shall constitute a separate and independent
obligation of the Company and shall continue in full force and effect notwithstanding any such judgment or order as aforesaid. The term
 &ldquo;rate of exchange&rdquo; shall include any premiums and costs of exchange payable in connection with the purchase of, or conversion
into, the relevant currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Compliance
with USA Patriot Act</I>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26,
2001)), the Agents are required to obtain, verify and record information that identifies their respective clients, including the Company,
which information may include the name and address of their respective clients, as well as other information that will allow the Agents
to properly identify their respective clients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>TMX
Group.</I> The Company hereby acknowledges that certain of the Agents, or affiliates thereof, may own or control an equity interest in
TMX Group Limited (&ldquo;<U>TMX Group</U>&rdquo;) and may have a nominee director serving on the TMX Group's board of directors. As
such, such investment dealers may be considered to have an economic interest in the listing of securities on any exchange owned or operated
by TMX Group, including the Toronto Stock Exchange, the TSX and the TSX Alpha Exchange. No person or company is required to obtain products
or services from TMX Group or its affiliates as a condition of any such dealer supplying or continuing to supply a product or service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Recognition
of the U.S. Special Resolution Regimes</I>. (i)&nbsp;In the event that any Agent that is a Covered Entity becomes subject to a proceeding
under a U.S. Special Resolution Regime, the transfer from such Agent of this Agreement, and any interest and obligation in or under this
Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement,
and any such interest and obligation, were governed by the laws of the United States or a state of the United States and (ii)&nbsp;in
the event that any Agent that is a Covered Entity or a BHC Act Affiliate of such Agent becomes subject to a proceeding under a U.S. Special
Resolution Regime, Default Rights under this Agreement that may be exercised against such Agent are permitted to be exercised to no greater
extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws
of the United States or a state of the United States. For the purposes of this Section&nbsp;7(j), a &ldquo;<U>BHC Act Affiliate</U>&rdquo;
has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).
 &ldquo;<U>Covered Entity</U>&rdquo; means any of the following: (i)&nbsp;a &ldquo;covered entity&rdquo; as that term is defined in, and
interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii)&nbsp;a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted
in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii)&nbsp;a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in
accordance with, 12 C.F.R. &sect; 382.2(b). &ldquo;<U>Default Right</U>&rdquo; has the meaning assigned to that term in, and shall be
interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable. &ldquo;<U>U.S. Special Resolution Regime</U>&rdquo;
means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank
Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Counterparts</I>.
This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable
document format (PDF) file.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Survival
of Provisions Upon Invalidity of Any Single Provision</I>. In case any provision in this Agreement shall be invalid, illegal or unenforceable,
the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Waiver
of Jury Trial</I>. Each of the Company and each of the Agents hereby irrevocably waives any right it may have to a trial by jury in respect
of any claim based upon or arising out of this Agreement or the transactions contemplated hereby or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Successors
and Assigns</I>. This Agreement will insure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees,
officers and directors and controlling persons referred to in Section&nbsp;5, and in each case their respective successors, and no other
person will have any right or obligation hereunder. No party may assign its rights or obligations under this Agreement without the prior
written consent of the other parties. The term &ldquo;successors&rdquo; shall not include any purchaser of the Shares as such from the
Agents merely by reason of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Titles
and Subtitles</I>. The titles of the sections and subsections of this Agreement are for convenience and reference only and are not to
be considered in construing this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><I>Entire
Agreement</I>. Other than the terms set forth in each Agency Transaction Notice delivered hereunder, this Agreement embodies the
entire agreement and understanding between the parties hereto and supersedes all prior agreements and understandings relating to the
subject matter hereof. This Agreement may not be amended or otherwise modified or any provision hereof waived except by an
instrument in writing signed by the Agents and the Company. Notwithstanding the foregoing, any party to this Agreement may update
its list of representatives on <U>Schedule 1</U> or their contact information by notice to the other parties to this Agreement given
in the manner provided for by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page&nbsp;follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please confirm that the foregoing
correctly sets forth the agreement between the Company and the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PROFOUND MEDICAL CORP.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;/s/ Arun Menawat</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-size: 10pt">Arun Menawat</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature page&nbsp;to
Equity Distribution Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Confirmed as of the date first above mentioned:</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">STIFEL NICOLAUS CANADA INC.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/
Brandon Roopnarinesingh</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-size: 10pt">Brandon Roopnarinesingh</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">STIFEL, NICOLAUS&nbsp;&amp; COMPANY,&nbsp;INCORPORATED</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Adam Kohn</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Adam Kohn</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page&nbsp;to Equity Distribution
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SCHEDULE 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AUTHORIZED COMPANY REPRESENTATIVES*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Name
    and Office / Title</FONT></TD>
    <TD STYLE="width: 41%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">E-mail
    Address</FONT></TD>
    <TD STYLE="width: 27%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Telephone
    Numbers</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">Arun
    Menawat, CEO</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">Rashed
    Dewan, CFO</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;*</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notices
to be provided to at least one of the above Company Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AUTHORIZED AGENT REPRESENTATIVES<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Authorized Agent Representatives of Stifel
Nicolaus Canada Inc. are as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Name
    and Office / Title</FONT></TD>
    <TD STYLE="width: 27%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">E-mail
    Address</FONT></TD>
    <TD STYLE="width: 27%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Telephone
    Numbers</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Brandon
    Roopnarinesingh, Director,&nbsp;Investment Banking</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Authorized Agent Representatives of Stifel,
Nicolaus&nbsp;&amp; Company,&nbsp;Incorporated are as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 46%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">Name and Office / Title</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 27%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">E-mail Address</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 27%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">Telephone Numbers</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">Daniel Covatta, Managing Director, Head of Special Situations</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">Adam Kohn, Managing Director, Healthcare Investment Banking</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">Mark White, Director, Special Situations</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">Suzanne Hill, Vice President, Special Situations</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">Nick Oust, Managing Director, Head of Healthcare Equity Capital Markets</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SCHEDULE 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
    of Subsidiary</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage
    Owned (Directly<BR>
    or Indirectly)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">Profound
    Medical Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Ontario</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">Profound
    Medical (U.S.) Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Delaware,
    USA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">Profound
    Medical Oy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Finland</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">Profound
    Medical GmbH</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Germany</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">Profound
    Medical Technology Services (Beijing) Co.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2753079 Ontario Inc.</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><FONT STYLE="font-size: 10pt">Ontario</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SCHEDULE 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PERMITTED FREE WRITING PROSPECTUSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[None.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXHIBIT&nbsp;A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROFOUND MEDICAL CORP.<BR>
2400 Skymark Avenue, Unit #6<BR>
Mississauga, Ontario L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[_______], 20[__]<BR>
[<FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT>] / [<FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[address] / [address]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VIA EMAIL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TRANSACTION NOTICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of this Transaction
Notice is to propose certain terms of the Agency Transaction entered into with Stifel / Stifel U.S. under, and pursuant to, that certain
Equity Distribution Agreement among the Company, Stifel, and Stifel U.S. dated September&nbsp;[<FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>], 2023 (the &ldquo;<U>Agreement</U>&rdquo;).
Please indicate your acceptance of the proposed terms below. Upon acceptance, the particular Agency Transaction to which this Transaction
Notice relates shall supplement, form a part of, and be subject to, the Agreement. Capitalized terms used but not otherwise defined herein
shall have the meanings ascribed to them in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the particular
Agency Transaction to which this Transaction Notice relates are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Trading Day(s)&nbsp;on which Shares may be Sold:</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">[_______], 20[____], [__________],<BR>
    20[____] . . . [________], 20[_____]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Maximum [Number]/[Value] of Shares<BR>
    to be Sold in the Aggregate:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[_______]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Maximum [Number]/[Value] of Shares<BR>
    to be Sold on each Trading Day:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[_______]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Stock exchange:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[_______]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Floor Price:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">USD[_____.___]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Placement Fee:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[__]%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of Page&nbsp;Intentionally Blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PROFOUND MEDICAL CORP.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and agreed as of<BR>
the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[<FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT>]
/ [<FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>tm2325456d1_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 40%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 20%; font-size: 10pt"><IMG SRC="tm2325456d1_ex99-3img001.jpg" ALT=""></TD>
    <TD STYLE="width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">200 Bay Street, South Tower</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Suite&nbsp;2800</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Toronto, ON</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">647 499 2828</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">mintz.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September&nbsp;6, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Profound Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2400 Skymark Avenue, Unit #6&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mississauga, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sirs/Mesdames:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>Re:</B></TD><TD STYLE="text-align: justify"><B>Profound Medical Corp. - Prospectus Supplement dated September&nbsp;6,
2023 to the Short Form&nbsp;Base Shelf Prospectus dated March&nbsp;23, 2022 (the &ldquo;Prospectus Supplement&rdquo;)</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the reference to our name
under the headings &ldquo;Documents Filed as Part&nbsp;of the Registration Statement&rdquo; and &ldquo;Interest of Experts&rdquo; and
the use of our opinion under the heading &ldquo;Eligibility for Investment&rdquo; in the Prospectus Supplement relating to the offering
of common shares of Profound Medical Corp. relating to the Registration Statement on Form&nbsp;F-10, as amended (File No.&nbsp;333-263248).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In giving this consent, we do not admit that we
are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Mintz LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mintz LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Los
Angeles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San Diego&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San
Francisco</FONT><FONT STYLE="text-transform: none">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;toronto&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Washington</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 8pt">MINTZ,
LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>tm2325456d1_ex99-4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit 99.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 12%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 48%; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Osler, Hoskin&nbsp;&amp; Harcourt <FONT STYLE="font-variant: small-caps">llp</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Box 50, 1 First Canadian Place<BR>
Toronto, Ontario, Canada&nbsp;&nbsp;M5X&nbsp;1B8<BR>
416.362.2111&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">main</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">416.862.6666&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">facsimile</FONT></P>
</TD>
    <TD STYLE="text-align: right; width: 40%; font-size: 10pt"><IMG SRC="tm2325456d1_ex99-4img001.jpg" ALT=""></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Toronto</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Montr&eacute;al</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Calgary</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ottawa</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vancouver</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New&nbsp;York</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 88%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">September 6, 2023</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound Medical Corp.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2400 Skymark Avenue, Unit #6</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mississauga, Ontario</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">L4W 5K5</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Sirs/Mesdames:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Profound Medical Corp. (the &ldquo;Issuer&rdquo;)</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We refer you to the prospectus supplement dated
    September&nbsp;6, 2023 to the short form base shelf prospectus of the Issuer dated March&nbsp;23, 2022 filed in all provinces and territories
    of Canada (the &ldquo;<B>Prospectus Supplement</B>&rdquo;), forming part of the Registration Statement on Form&nbsp;F-10, as amended (Registration
    No.&nbsp;333-263248) filed by the Issuer with the U.S. Securities and Exchange Commission.
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the references to this firm
    under the headings &ldquo;Documents Filed as Part&nbsp;of the Registration Statement&rdquo; and &ldquo;Interest of Experts&rdquo; and
    to the reference to and use of our opinion under the heading &ldquo;Eligibility For Investment&rdquo; in the Prospectus Supplement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In giving this consent, we do not thereby admit
    that we come within the category of persons whose consent is required by the <I>Securities Act</I> of 1933, as amended, or the rules&nbsp;and
    regulations promulgated thereunder.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours very truly,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>/s/ &ldquo;Osler, Hoskin&nbsp;&amp; Harcourt
    LLP&rdquo;</I></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Osler, Hoskin&nbsp;&amp; Harcourt LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GW</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">osler.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2325456d1_ex99-3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2325456d1_ex99-3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Z 'H# 2(  A$! Q$!_\0
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**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2325456d1_ex99-4img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2325456d1_ex99-4img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  C 'P# 2(  A$! Q$!_\0
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BR/SK(TV\N8H)(A/(R1R%5WMO(''<Y)HHJ):,W@VXM,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2325456d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2325456d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M 6 # 2(  A$! Q$!_\0
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ML]2O+>+[,AV0SLBYYYP#7H7PQN[F]\"V<]W<2SS,\@,DKEF.'/<UY?\ &/\
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MT4@]B=P/\A6%\8]:BU#Q-!80L&6PC*N1VD8Y(_ !?QS75_!337M]!O\ 4'7
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MT;[!9?\ /I!_W['^%17,&F6=K+<W$%M'#$A=W:,84 9)Z5P>TP__ #[?W_\
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;7N-(      .@%+7G8BO*O/FD=]"C&C'E1__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
